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Natürlich vorkommende CD4+CD25+Foxp3+ regulatorische T Zellen (Treg) besitzen die 
Fähigkeit, Immunantworten, wie z.B. die Tumorabwehr, zu unterdrücken. In klinischen Studien 
in Krebspatienten wird gegenwärtig untersucht, ob durch Manipulation der Treg Population die 
Wirksamkeit von Vakzinen, deren Ziel die Stärkung des adaptiven Immunsystems ist, gesteigert 
werden kann. Viele Tumore verlieren jedoch die Expression von MHC Klasse I Molekülen, die 
zur direkten Erkennung und Eliminierung durch CD8+ T Zellen führen. Eine effiziente 
Beseitigung dieser Art von Tumoren kann allerdings durch Zellen des angeborenen 
Immunsystems erfolgen, die nicht auf die Erkennung von Antigen-MHC Klasse I Komplexen 
angewiesen sind. Die Funktion regulatorischer T Zellen in der Abwehr von Tumoren, deren 
Wachstum überwiegend durch das angeborene Immunsystem kontrolliert wird, ist bislang nur 
sehr wenig erforscht. 
 
In dieser Arbeit wurde der Einfluss von Treg auf die Immunantwort gegen subkutan injizierte 
RMA-S Zellen untersucht. RMA-S Zellen sind Maus-Lymphom-Zellen, die nur eine geringe 
MHC Klasse I Expression aufweisen. Unsere Experimente zeigten, dass sich Treg im 
Tumorgewebe sowie in den lymphoiden Organen Tumor-tragender Mäuse anreichern. Die 
Depletion von Treg mittels eines monoklonalen anti-CD25 Antikörpers ermöglichte die 
Abstoßung großer Mengen injizierter RMA-S Zellen, die in unbehandelten Mäusen zu 
progressivem Tumorwachstum führten. In Abwesenheit von Treg wurde eine sehr hoher Anzahl 
an NK1.1+, CD8+ und CD4+CD25+ T Zellen in das Tumorgewebe rekrutiert. Alle diese 
Zellpopulationen waren an der Abstoßung von RMA-S Tumoren beteiligt. Die in Abwesenheit 
der Treg ausgelöste primäre Immunantwort führte zur Entstehung von immunologischem 
Gedächtnis; In Mäusen, die den ursprünglichen Tumor abgestoßen hatten und anschließend 
erneut mit entweder RMA-S oder MHC Klasse I exprimierenden RMA Zellen injiziert wurden, 
wurde Tumorabstoßung beobachtet. Darüber hinaus konnten wir zeigen, dass Tumor-
infiltrierende Leukozyten nach Depletion von Treg IFN-γ in größeren Mengen produzierten. Eine 
Neutralisation von IFN-γ hemmte die Anreicherung von Leukozyten im Tumor und verhinderte 
die normalerweise nach Treg Depletion beobachtete Tumorabstoßung. In Abwesenheit von Treg 
stellten Makrophagen die größte Zell-Population unter den Tumor-infiltrierenden Leukozyten 
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dar. Makrophagen, die in Tumore Treg-depletierter Mäuse eingewandert waren, zeigten eine 
verstärkte Expression von MHC Klasse II und eine gesteigerte Produktion von Chemokinen und 
Entzündungs-fördernden Zytokinen. Diese Makrophagen waren in der Lage die Proliferation von 
Tumorzellen durch einen Mechanismus zu unterbinden, der unabhängig von iNOS, PGE2 und 
IDO war. 
 
Diese Arbeit untermauert somit die Bedeutung von Treg für die Hemmung der Immunantwort 
gegen Tumorzellen mit geringer MHC Klasse I Expression. In Abwesenheit von Treg bestand 
zudem eine Korrelation zwischen einer hohen Anzahl Tumor-infiltrierender Makrophagen und 
der Abstoßung des Tumors. Diese Daten beschreiben zum ersten Mal dass in Tumor-tragenden 
Mäusen Makrophagen durch Treg gehemmt werden können. 
 
Der zweite Teil dieser Arbeit diente der Untersuchung weiterer Kontrollmechanismen der 
Immunantwort gegen RMA-S Tumore.  Hierbei konzentrierten wir uns auf die Bedeutung von 
endogen produzierten Typ I Interferonen. Obwohl die exogene Applikation von Typ I 
Interferonen bereits zur Behandlung verschiedener Krebsarten angewandt wird, ist ihre endogene 
Produktion und Funktion nur sehr wenig erforscht. In diesen Experimenten untersuchten wir das 
Tumorwachstum von RMA-S Tumoren in IFNAR1-/- Mäusen, die nicht auf Typ I Interferone 
reagieren können, da sie keinen Rezeptor für Typ I Interferone exprimieren. In IFNAR1-/- 
Mäusen stellten wir ein beschleunigtes Tumorwachstum fest. Wir generierten Knochenmark-
Chimären, in denen entweder die hämatopoetischen oder die nicht-hämatopoetischen Zellen 
unfähig waren auf Typ I Interferon zu reagieren und beobachteten, dass die Fähigkeit zur 
Reaktion auf Typ I Interferone in beiden Zellpopulationen gegeben sein muss. Der IFNA-
Rezeptor zeigte sich insbesondere für die zytotoxische Aktivität von NK Zellen und für eine 
fehlerfreie Entwicklung von Blutgefäß-Netzwerken verantwortlich. Im Gegensatz hierzu 
beeinträchtigte seine Abwesenheit weder die Effektorfunktionen von Makrophagen noch die 
Anreicherung von Leukozyten im Tumorgewebe. 
Zusammenfassend zeigten unsere Studien, dass endogen produzierte Typ I Intereferone einen 
Beitrag zur Kontrolle des Wachstums von RMA-S Tumoren ohne MHC Klasse I Expression 
leisten. Dies könnte durch Beeinflussung sowohl der hämatopoetischen wie auch der nicht-
hämatopoetischen Zellen und durch Regulation der Aktivität von NK Zellen und der Bildung 
Tumor-versorgender Blutgefäße geschehen. 




Naturally occurring CD4+CD25+Foxp3+ regulatory T cells (Treg) have been shown to suppress 
immune responses, including anti-tumor immunity. Strategies of manipulating Treg in cancer 
patients are currently evaluated in clinical trials with the aim of enhancing the efficiency of 
vaccinations, targeting the adaptive arm of immunity. Many tumors, however, lose expression of 
MHC class I and thus become protected from CD8+ T cell-mediated recognition and elimination. 
Such types of tumors can still be efficiently eliminated by cells of the innate immune system, in 
particular NK cells, through antigen- and MHC class I-independent mechanisms. The role of 
Treg in the rejection of tumors, which are predominantly under the control of innate immune 
cells has been poorly addressed so far.  
 
In this study, we investigated the influence of Treg on the immune response against the MHC 
class I-deficient mouse lymphoma RMA-S after subcutaneous injection. We showed that Treg 
accumulate in the tumor tissue and lymphoid organs of tumor-bearing animals. Treg depletion 
upon application of an anti-CD25 monoclonal antibody led to the rejection of high tumor cell 
numbers, which in contrast grew progressively in untreated mice. Our experiments demonstrated 
that NK1.1+ cells, CD8+ and CD4+CD25- T cells are recruited in high cell numbers to the tumor 
site in the absence of Treg and that all of these three cell populations contribute to RMA-S tumor 
rejection. Primary immune responses elicited during Treg depletion led to the generation of 
protective immunological memory; rechallenge of mice that had rejected the initial tumor with 
either RMA-S or MHC class I-sufficient RMA tumor cells resulted in immediate tumor rejection. 
Furthermore, we showed that IFN-γ is produced in higher amounts by the tumor-infiltrating 
lymphocytes in the absence of Treg. Neutralization of IFN-γ completely abrogated the tumor 
rejection observed after Treg depletion, which correlated with the inhibition of accumulation of 
leukocytes at the tumor site. Among the tumor-infiltrating leukocytes, macrophages constituted 
the major cell population infiltrating the RMA-S tumor tissue in the absence of Treg. Tumor-
infiltrating macrophages from Treg depleted mice expressed increased amounts of MHC class II 
and produced highly enhanced levels of chemokines and pro-inflammatory cytokines as 
compared to control mice. Macrophages isolated from the tumors also inhibited tumor cell 
proliferation through a mechanism independent of iNOS, PGE2 and IDO. 
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In conclusion, this study supports a role for Treg in blunting the immune response to a MHC 
class I-deficient tumor target, by interfering with leukocyte accumulation at the tumor site. In 
addition, high numbers of activated tumor-infiltrating macrophages correlated with tumor 
rejection in the absence of Treg. These data identify macrophages as novel potential targets for 
Treg mediated immune suppression in cancer.  
 
In the second part of this study, we aimed at defining further mechanisms controlling the immune 
response against the MHC class I-deficient RMA-S tumor. For this purpose, we focused on the 
role of endogenously produced type I IFN. Although exogenously administered type I IFN have 
been used to treat various types of cancer, their endogenous production and function during an 
anti-tumor response has not been extensively studied. We studied the growth of RMA-S tumor in 
mice that cannot respond to type I IFN (IFNAR1-/- mice) and observed an acceleration in the 
tumor growth. In addition, we prepared bone marrow chimeras in which either the hematopoietic 
or the non-hematopoietic cells cannot respond to type I IFN and we found that type I IFN 
responsiveness is required in both compartments. Namely, IFNAR1 was important for NK cell 
cytotoxicity and proper development of the vessel network in the tumor tissue. In contrast, its 
absence did neither affect macrophage effector functions nor accumulation of leukocytes within 
the tumor tissue. 
In summary, endogenously produced type I IFN contribute to the control of the MHC class 
I-deficient RMA-S tumor growth, via targeting both the hematopoietic and non-hematopoietic 
compartments, and regulate NK cell activity and tumor vessel formation. 
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3 INTRODUCTION 
3.1 The immune system 
The immune system is a complex and highly developed system, which has evolved to protect the 
host against the attack of foreign pathogens as well as tumors. In vertebrates, it consists of the 
innate and the adaptive immunity. The non-specific component of the immune system – innate 
immunity – is a set of mechanisms that are not specialized for a particular pathogen. Adaptive 
immunity, on the contrary, displays a higher degree of specificity in recognizing foreign antigens 
than innate immunity as well as the property of memory. Typically, an adaptive immune response 
against an antigen is raised five or six days after the initial exposure to that antigen. Subsequent 
exposure to the same antigen results in a memory response, which is faster, stronger, and often 
more effective in neutralizing or clearing the pathogen than the first one. Due to this attribute, the 
immune system can confer life-long immunity to many infectious agents after an initial 
encounter. Adaptive and innate immunity, however, do not operate independently of each other 
but rather function as a highly interactive and cooperative system. 
The cells of the immune system originate in the bone marrow (BM), where many of them 
also mature, from the same progenitor, the hematopoietic stem cells. Initially, they give rise to 
stem cells of more limited potential, i.e. the common myeloid progenitor and the common 
lymphoid progenitor. The first one is the precursor of granulocytes, macrophages, dendritic cells 
(DC) and mast cells, while the second one gives rise to the lymphocytes. 
 
3.1.1 The immune response to tumors 
In order to fulfill its role, the immune system has developed mechanisms for the discrimination of 
self and non-self antigens, preventing the host from suffering autoimmune diseases via tolerance 
to self-antigens, while recognizing and eliminating the foreign pathogens. Cancer cells can be 
viewed as altered self-cells that have escaped normal growth-regulating mechanisms. 
The theory of immune surveillance suggests that cancer cells arise frequently in the body, 
are recognized as foreign and are eliminated by the immune system; when tumor cells escape 
immune surveillance, tumors form that grow too large for the immune system to control. A more 
elaborate theory on how the immune system responds to a tumor is cancer immunoediting 1-5, 
which is comprised of three phases: elimination, equilibrium and escape. The elimination phase 
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basically refers to the immune surveillance. In the equilibrium phase, the tumor cell variants that 
have survived the elimination phase and the immune system enter into a dynamic equilibrium 
leading to a population of tumor clones with reduced immunogenicity. Evidence for the 
equilibrium phase was provided by a clinical case where metastatic melanoma occurred 1-2 years 
post-transplant in the two recipients who each received a kidney from the same donor 6. In the 
escape phase, finally, the tumor cell variants surviving the equilibrium phase grow and become 
clinically detectable (Figure 3.1). 
 
 
Figure 3.1. The three Es of cancer immunoediting: elimination, equilibrium, and escape. (Dunn et al. Annu Rev 
Immunol. 2004;22:329-60) 
 
The immune system can detect the tumor cells by the recognition of the so called tumor-
specific antigens (TSA) or tumor-associated antigens (TAA). TSA are unique to tumor cells and 
not present on normal cells, while TAA are not unique to tumor cells but quite often proteins 
either expressed at low levels by normal cells or expressed on normal cells during fetal 
development when the immune system is immature to respond. However, the tumor can impede 
the immune response directly e.g. by the shedding of recognition structures or indirectly e.g. by 
the production of immunosuppressive cytokines (TGF-β, IL-10) or the induction of 
immunosuppressive cell populations. 
The immune system itself can form tumors that are classified as lymphomas or leukemias. 
Lymphomas are solid tumors which form within a lymphoid tissue, such as the bone marrow, 
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lymph nodes or thymus, while leukemias – either of lymphoid or myeloid lineage – proliferate as 
single cells. 
 
3.1.2 The innate immune system 
The innate immune system is a collection of distinct subsystems that appeared at different stages 
of evolution including anatomic, physiologic, phagocytic and inflammatory barriers that prevent 
the entrance and establishment of infectious agents. A summary of the main subsystems found in 
mammals and their function in innate host defence can be found in Table 3.1. 
Innate immune recognition is also known as pattern recognition and is based on the 
detection of molecular structures unique to microorganisms. The innate immune system senses 
pathogens through pattern-recognition receptors (PRR), which trigger the activation of 
antimicrobial defenses. The targets of PRR are named pathogen-associated molecular patters 
(PAMP), although they are present on both pathogenic and non-pathogenic microorganisms. 
Bacterial PAMP are often components of the cell wall, such as lipopolysaccharide (LPS), 
peptidoglycan, lipoteichoic acids and cell-wall lipoproteins. β-glycan is an important fungal 
PAMP, which is present on the fungal cell wall. The detection of these structures by the innate 
immune system can signal the presence of microorganisms. Moreover, the recognition of viruses 
also follows this principle; however, since viral components are synthesized within the host cells, 
the main targets of innate immune recognition in this case are the viral nucleic acids. In addition, 
the innate immune system is able to discriminate between self and viral nucleic acids based on 
specific chemical modifications unique to viral RNA and DNA, as well as on the cellular 
compartments where viral, but not host-derived, nucleic acids are found 7. There are several 
classes of PRR, the best characterized being Toll-like receptors (TLR), which can elicit 
inflammatory and antimicrobial responses after activation by their microbial ligands 8. 
The innate immune response depends on the coordinate activity of several effector cells, 
like natural killer cells, monocytes/macrophages, DC and granulocytes. 
 
3.1.2.1 Natural Killer cells 
Natural Killer (NK) cells constitute one of the major lymphocyte populations, 
representing 5-10% of cells among peripheral blood lymphocytes (PBL). They differ from the 
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other lymphocytes by the absence of clonally distributed receptors derived via somatic gene 
rearrangement. NK cells were first described in the early 1970’s by R. Kiessling and R.B. 
Herberman 9-12 and defined based on their functional entity, i.e. cells that are capable of 
recognizing and  killing  tumor cells without a prior exposure. Afterwards, they were described to  
  
Table 3.1. Subsystems of the innate immune system. (Adapted from R. Medzhitov, Nature, 2007 ) 
Innate subsystem Primary sensors Prototypical responses 
Mucosal epithelia TLR and NOD proteins 
Production of antimicrobial peptides  
Production of mucins 
Phagocytes 
TLR, dectins and NOD 
proteins 
Production of antimicrobial proteins  
Production of cytokines: IL-1β, IL-6 and 
TNF 
Acute-phase proteins and 
complement system 
Collectins, pentraxins and 
ficolins 
Lysis or opsonization of pathogens  
Chemotactic attraction of leukocytes 
Inflammasomes NALP and NAIP 
Production of IL-1-family members  
Apoptosis of infected host cells 
NK cells ND Apoptosis of infected host cells 
Type-I-IFN-induced antiviral 
proteins 
RIG-I, MDA5, DAI and 
TLR 
Induction of an antiviral state  
Apoptosis of infected host cells 
Eosinophils and basophils ND 
Contraction of smooth muscle  
Production of mucins  
Peristalsis  
Production of biogenic amines  
Production of cytokines: IL-4, IL-5, 
IL-9, IL-13 and TNF 
Mast cells ND 
Contraction of smooth muscle  
Production of mucins  
Peristalsis  
Production of biogenic amines  
Production of cytokines: IL-4, IL-5, 
IL-9, IL-13 and TNF 
ND, not determined 
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have a large granular lymphocyte morphology 13. Phenotypically, they are defined as CD3-CD56+ 
cells in humans 14, and can be further divided into two subpopulations, the CD56brightCD16- 
subset, which can be found mainly in the LN and produces high amounts of cytokines, and the 
CD56dimCD16+ subset which is found predominantly in the blood and is cytolytic. There are 
indications that CD56bright NK cells could be precursors of the CD56dim subset 15. In mice, 
depending on the strain, the combination of CD3-NK1.1+ or CD3-DX5+ is commonly used to 
identify NK cells. Recently, NKp46 (CD335) has been described to be uniquely expressed on NK 
cells of various species, including human and mice 16. Importantly, NKp46 is not expressed on 
NKT cells, a population that shares many common markers with NK cells, such as NK1.1. 
NKp46 appears early during NK cell development, so it can be used to characterize NK cells of 
different maturation stages. 
Stages of NK cell development have been described based on phenotypical and functional 
analysis 17. Committed NK cell progenitors express CD122 and no other lineage-specific markers 
(stage I). Subsequently, immature NK cells express NK1.1 – only on the C57BL/6 strain – (stage 
II) followed by the acquisition of the whole repertoire of activating and inhibitory receptors of the 
CD94-NKG2 and Ly49 families (stage III). DX5 appears on stage IV and NK cell maturation is 
completed with the expression of the markers CD11b and CD43, which accompanies acquisition 
of cytotoxicity and the ability to produce cytokines (stage V). In mice, it has been reported that 
the mature CD11bhigh NK cell population can be further distinguished into two phenotypically 
and functionally distinct subsets based on the expression of the marker CD27 18. The 
CD11bhighCD27high NK cell population exhibited enhanced effector functions, i.e. higher 
cytotoxic ability and enhanced IFN-γ production upon stimulation with IL-12 and IL-18 in vitro, 
when compared to the CD11bhighCD27low NK cell subset. In addition, CD11bhighCD27high NK 
cells specifically expressed the chemokine receptor CXCR3 and possessed higher proliferating 
activity 18. Similar subdivision was also proposed for human NK cells 19. Stimulation of NK cells 
with CD27 ligand (CD70) artificially expressed on tumor cells could enhance proliferation and 
IFN-γ production of freshly isolated NK cells and potentated the rejection of MHC class I-
deficient tumor cells via perforin- and IFN-γ- dependent mechanisms 20. 
NK cells require interaction with bone marrow stromal cells for functional maturation 
21,22. Their development is mainly independent of the thymus, since they appear in normal 
numbers and function in athymic (nude), SCID and, RAG1-/- and RAG2-/- mice. Nevertheless, 
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there is accumulative evidence that not all of the NK cells derive from a unique peripheral pool. 
‘Bipotent’ NK cell – T cell progenitors have been described in the thymus in both humans and 
mice 23-25. Mouse thymic NK cells were shown to be different from BM NK cells, with regards to 
higher expression of GATA-3 and CD127 (IL-7Rα) and to their preferential homing to the lymph 
nodes. They exhibited low cytotoxic ability and high IFN-γ production, resembling the 
CD56highCD16- human NK cell subset 26. Mouse liver contains a NK cell subset, which does not 
express the DX5 marker and constitutively expresses TRAIL. This effector molecule may be 
involved in the immunosurveillance of liver tumors 27. In addition, a CD34+ subset which can 
differentiate into the CD56bright NK cell subset was identified in human LN 28. 
There are various mutations described causing impairment of NK cell numbers and/or 
function. Lists of genes coding for different transcription factors, surface receptors or cytokines 
leading to such impairments are shown in Tables 3.2-3.4. 
 
Gene deleted Effect Reference 
Ikaros NK cells absent 29, 30 
PU.1 NK cell number decreased, normal 
lytic function 
31 
Ets-1 NK cell number decreased, decreased 
lytic function 
32 
Id2 NK cell number decreased or absent, 
reduced lytic function 
33, 34 
TCF-1 Altered acquisition of Ly49s 34, 35 
IRF-1 NK cell number decreased, lytic 
function impaired 
36, 37 
IRF-2 NK cell number decreased, lytic 
function impaired 
38 
Table 3.2. Transcription factor deficiencies leading to NK cell impairments. 
 
Gene deleted Effect Reference 
LTβr NK cells severely decreased 39 
LTα1β2 NK cells severely decreased, reduced 
lytic function 
40, 41, 42 
IL-15Rα NK cells severely decreased 43 
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IL-2/15Rβ NK cells absent 44, 45 
c-kit NK cells decreased, impaired lytic 
function 
46 
Table 3.3. Surface receptor deficiencies leading to NK cell impairments. 
 
Gene deleted Effect Reference 
IL-15 NK cells absent, no lytic function 47, 48 
Flt3-ligand NK cells severely decreased, impaired 
lytic function 
49 
Table 3.4. Cytokine deficiencies leading to NK cell impairments. 
 
3.1.2.1.1 NK cells and tumor 
NK cells were the first cells shown to effectively eliminate tumor cells from the 
circulation of mice 50,51. Mice with an autosomal mutation called beige lack NK cells, and are 
more susceptible than normal mice to tumor growth following injection with live tumor cells 52. 
Likewise, humans suffering from the Chediak-Higashi syndrome, an autosomal recessive 
disorder associated with impairment in neutrophils, macrophages and NK cells, have an increased 
incidence of lymphomas 53.  
NK cells, unlike CD8+ T cells, do not require expression of MHC class I determinants for 
recognition of target cells. In fact, there is an inverse relationship between expression of MHC 
class I and susceptibility to lysis by NK cells. This observation is the milestone for the ‘missing 
self hypothesis’ 54, describing that cells which have normal expression of MHC class I molecules 
are not lysed by NK cells, while if self is absent, NK cells are activated to lyse the abnormal 
cells. Reduced MHC class I expression is often observed in virus-infected cells and tumor cells, 
which downregulate MHC class I expression as a mechanism to escape CD8+ T cell-mediated 
lysis. Thus, NK cells can kill virus-infected or transformed cells 55 and are especially effective at 
killing cells with low MHC class I expression 54,56. More recent studies confirmed the importance 
of NK cell cytotoxicity – mediated via perforin – against MHC class I-deficient tumors in vivo 57-
59. Besides perforin, NK cells can express death ligands, i.e. CD95L, TNF-α and TNF-related 
apoptosis-inducing ligand (TRAIL), via which they can induce apoptosis to their targets 60-62. 
The more recent concept about NK cell recognition of targets involves a set of activating 
receptors which stimulate NK cell functions, in addition to the inhibitory receptors, which sense 
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the absence of MHC class I 63,64. The dynamic balance between these activating and inhibitory 
signals controls NK cell activation (Figure 3.2). 
 
Figure 3.2. Control of NK cell functions by the balance of activating and inhibitory signals (Smyth MJ et al. Nature 
Reviews Cancer 2, 850-861). 
 
NKG2D is an example of an activating receptor expressed on human and mouse NK cells 
that recognize a diversity of ligands, including the RAE-1 family (α, β, γ, δ and ε), H60 and 
MULT-1 in the mouse and the MICA and ULBP families in humans 65,66. NKG2D ligands are not 
expressed on the surface of normal cells, but their expression is induced in virally infected, 
stressed and DNA damaged cells 65-68. In tumor cell lines that fail to express NKG2D ligands, 
ectopic expression of RAE-1 leads to their elimination in vivo 69,70. Moreover, NKG2D 
neutralization led to increased incidence of methylcholanthrene (MCA)-induced fibrosarcomas 71. 
Finally, increased incidence of tumors was observed in NKG2D-deficient mice 72. 
Although tumors quite often bear recognition structures for NK cells, they might escape 
NK cell killing by desensitizing the receptor via soluble ligands released by the tumor cells, as in 
the case of the NKG2D pathway; in individuals with epithelial derived tumors, soluble, surface-
shed MICA was detected in the sera and resulted in down-regulation of NKG2D and subsequent 
impairment of NK cell cytotoxicity 73. In cancer patients, NK cell function was shown to be 
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impaired, as determined by reduced proliferation, response to IFN and cytotoxicity after ex vivo 
isolation of the cells 74,75. Nevertheless, in a 11-year follow-up study of a Japanese population, 
medium and high cytolytic function of peripheral blood NK cells was associated with reduced 
cancer risk, while low cytolytic function was associated with increased cancer risk 76.  
Several studies aim at improving the anti-tumor effect of NK cells for cancer 
immunotherapy. These approaches include endogenous activation of NK cells via the 
administration of cytokines 77-79 or adoptive transfer of ex vivo expanded and activated NK cells 
80,81. Unfortunately, the application of IL-2 for the activation of NK cells has been controversial 
because of its accompanying toxicity in vivo. In addition, adoptive immunotherapy of cancer with 
systemic administration of autologous NK cells has also proven to be not so successful, as the 
cells are difficult to expand and localize poorly to the tumors. Based on this observation, it is 
necessary to develop alternative approaches to enhance anti-tumor immunity. 
 
3.1.2.1.2 NK cells as regulatory cells 
Besides their ability to lyse target cells, an important function of NK cells is the production of 
cytokines, such as IFN-γ, TNF-α and GM-CSF. In the past few years, evidence for a role for NK 
cells in promoting adaptive immune responses via their interaction with DC has been reported 82-
87. These data have provided a new appreciation for the interrelated nature of innate and adaptive 
immunity. NK cells were shown to kill immature DC, despite high expression of MHC class I 83. 
It has also been described that NK cells with an immature phenotype were found in increased 
numbers in a leukemia mouse model and these immature NK cells could suppress DC functions, 
rather than killing them, by down-regulating the expression of I-Ad or inhibiting allo-T cell 
stimulatory activity 88. During early pregnancy in humans and rodents, 
c-kit+CD25+CD122+CD16-CD56bright NK cells and Thy-1+NK1.1+asialo-GM1+ cells, 
respectively, were reported to accumulate in the uterine deciduas 89,90. These uterine NK cells 
produce TGF-β1 and are thought to have immunoregulatory functions 91-93. Finally, NK cells are 
thought to play an immunoregulatory role in the prevention of autoimmune diseases, as 
autoimmune condition is typically deteriorated when there are NK cell defects 94. 
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3.1.2.2 Macrophages 
Macrophages originate from the common myeloid progenitor in the bone marrow. They are then 
released in the blood where they differentiate into mature monocytes, comprising ~5% of 
peripheral blood leukocytes. When monocytes migrate into the tissues, they eventually 
differentiate into tissue-specific macrophages. This process is accompanied by several changes: 
increase in size, increase in number and complexity of organelles, acquisition of phagocytic 
ability and secretion of various soluble factors. Macrophages serve different functions in various 
tissues, such as alveolar macrophages in the lung, histiocytes in connective tissues, Kupffer cells 
in the liver, mesangial cells in the kidney, microglial cells in the brain and osteoclasts in the 
bones. 
 Monocytes/macrophages are identified by the expression of CD14 marker in humans and 
F4/80 marker in mice 95. In addition, macrosialin or CD68, a lysosomal marker, can be used to 
identify all tissue macrophages of both mouse and human origin 96. Nevertheless, peripheral 
blood monocytes are not a homogeneous population and they can be divided into two functional 
subsets in mice; a CX3CR1lowCCR2+Gr-1+ ‘inflammatory subset’ which has a short half-life and 
is actively recruited to inflamed tissues, and a CX3CR1highCCR2-Gr-1- ‘resident subset’ which 
has a longer half-life and is recruited to non-inflammed tissues in a CX3CR1-dependent manner 
97. Both subsets have the potential to differentiate in vivo into DC. In addition, the level of 
expression of CX3CR1 correlates with the two described monocyte subpopulations in humans, 
the CD14+CD16- and CD14lowCD16+ subsets, resembling the murine inflammatory and resident 
subsets, respectively. 
 Macrophages can be activated via various stimuli during an immune response, which 
determine their subsequent phenotype. Macrophage activation can be triggered via TLR 
pathways (see Table 1.1) and/or cytokines secreted by lymphocytes, the most potent of which is 
IFN-γ 98. Activation of macrophages via LPS, a ligand for TLR4, and IFN-γ leads to the 
‘classically’ activated macrophages, also known as M1, which are linked to the response to 
intracellular pathogens and promote Th1 responses. They are characterized by their ability to 
secrete significant amount of proinflammatory cytokines, such as IL-1β, IL-15, IL-18, TNFα and 
IL-12, and the enhanced expression of MHC class II and co-stimulatory molecules CD80 and 
CD86 95. By contrast, an ‘alternative’ activation pathway has also been described. Such 
macrophages are associated with parasitic infections, allergic and humoral responses 99. More 
recently, the alternatively activated macrophages or M2 have been further subdivided into 3 
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categories depending on the activation trigger: M2a macrophages arise after exposure to IL-4 or 
IL-13, M2b macrophages after engagement of Fcγ receptors in combination with IL-1β or LPS, 
and M2c macrophages are induced by IL-10, TGF-β or glucocorticoids 95. The activation pattern 
of macrophage populations in tumors is not so well defined, but in some cases it bears similarities 
with the alternative activation phenotype. 
Activated macrophages can produce cytotoxic substances which can be divided into 
oxygen-dependent and oxygen-independent. Oxygen-dependent substances include the reactive 
oxygen intermediates, such as hydrogen peroxide (H2O2) and the reactive nitrogen intermediates, 
such as nitric oxide (NO). NO is produced by the enzyme inducible nitric oxide synthase (iNOS) 
via the following reaction: 
L-arginine + O2 + NADPH → NO + L-citrulline + NADP 
The oxygen-independent substances include various hydrolytic enzymes, such as lysozyme, 
various antimicrobial and cytotoxic peptides, known as defensins, and cytokines, such as TNF-α. 
Only a limited number of mutations which lead to macrophage deficiency have been 
described. In the osteopetrotic op/op mouse, a naturally occurring mutation of the gene coding for 
colony stimulating factor (CSF)-1 leads to differential deficiency of various macrophage 
subpopulations, dividing the macrophage lineage into CSF-1-dependent and CSF-1-independent 
100. The PU-1 knockout mouse, in contrast, was artificially generated 101. PU.1 is a transcription 
factor specifically expressed in hematopoietic cells. Homozygosity for the mutant gene leads to 
lethality in mice in the prenatal stage; nevertheless, analysis of embryos up to day 18 of gestation 
revealed that no macrophages could be detected in these mice. The development of liposome-
encapsulated clodronate (dichloromethylene diphosphonate) is the most commonly used method 
to eliminate macrophages in vivo 102. 
 
3.1.2.2.1 Tumor associated macrophages 
The tumor microenvironment has many factors that can recruit and differentiate the infiltrating 
macrophages, which are defined as tumor-associated macrophages (TAM) 103. TAM quite often 
represent the major infiltrating cell population of various tumors, and can exert tumor promoting 
or tumor suppressing functions. 
TAM isolated from mice bearing mammary tumors were shown to be poor producers of 
NO and exhibited low cytotoxic ability 104. In addition, macrophages positive for iNOS were 
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rarely found in human ovarian cancer and were only localized in the periphery 105. Induction of 
angiogenesis by the production of angiogenic factors such as vascular epithelial growth factor 
(VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) has often been linked 
with the TAM. In breast cancer patients, TAM density positively correlated with VEGF 
expression and microvessel density, while all of them negatively correlated with disease-free 
survival 106. TAM have been shown to express high levels of both the scavenger receptor A 107 
and the mannose receptor 95, which is compatible with the M2 macrophage phenotype. 
On the other hand, TAM have the potential to directly control tumor cell proliferation 
when appropriately stimulated, and thus exert tumor suppressing functions. In two murine models 
of melanoma, engineered to produce granulocyte/macrophage-CSF (GM-CSF), macrophage 
density inversely correlated with tumorigenicity; these macrophages produced macrophage 
metalloelastase (MME or MMP-12) and angiostatin, which suppressed the growth of metastases 
108. MHC class II-negative myeloma cells injected into mice were readily infiltrated by 
macrophages and were crucial in inhibiting tumor growth after activation by CD4+ T cell-derived 
IFN-γ 109. Finally, CpG-oligodeoxynucleotide treatment allowed the control of weakly 
immunogenic tumors, such as the B16 melanoma and the NXS2 neuroblastoma by macrophages 
110. 
 
3.1.2.2.2 Myeloid-Derived Suppressor Cells 
In cancer patients and tumor-bearing mice, a subpopulation of myeloid cells, characterized as 
myeloid-derived suppressor cells (MDSC), myeloid suppressor cells (MSC) or immature myeloid 
cells (iMC), has been described to accumulate and exert immunosuppressive function 111,112. 
MDSC represent a heterogeneous population of myeloid cells comprising of immature 
macrophages, granulocytes and DC; the addition of cytokines is able to differentiate these cells 
into mature macrophages, granulocytes or DC in vitro 113. In mice, MDSC are identified by the 
expression of the markers CD11b and Gr-1, while other markers have also been described for this 
population, such as CD31 113, CD115 114 and CD124 114. Interestingly, this population can be 
detected in low numbers also in the BM, blood and spleen of healthy mice, lacking however 
immunosuppressive function. Human equivalent MDSC were originally described in patients 
with head and neck cancer as CD34+ cells 115. Afterwards, they were also characterized in the 
peripheral blood of patients with squamous cell carcinoma, non-small cell lung cancer and breast 
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cancer 116. Human MDSC also exhibit an immature phenotype, as shown by the expression of the 
markers CD34, CD33, CD13 and the absence of CD15. 
 Accumulating findings suggest that tumor-derived factors are responsible for the 
generation of MDSC. Conditioned media from tumor cell lines could inhibit the differentiation of 
DC from their precursors in vitro 117. In addition, immunosuppressive cells arose from bone 
marrow cells after culture with Lewis lung carcinoma S/N 118. MDSC expansion in tumor-bearing 
hosts has been correlated with T cell dysfunction. Indeed, it was shown that MDSC induce 
decrease or loss of the expression of the TCR ζ chain 119, inhibit the CD3/CD28-induced T cell 
proliferation by the production of nitrogen and oxygen intermediates 120 as well as the CD8+ T 
cell IFN-γ production 121. Recently, it was shown that MDSC suppress IL-2-mediated NK cell 
cytotoxicity via interfering with Stat5 activation 122. For this purpose, depletion of MDSC in 
therapeutic settings is under investigation. In mice, an anti-Gr-1 mAb has been used to deplete 
MDSC and enhance anti-tumor responses 123. However, a similar treatment is difficult to be 
applied in humans, since total granulocyte depletion removes also neutrophils which could render 
the individual susceptible to infections. 
 
3.1.3 The adaptive immune system 
The two main components of the adaptive immune system are B and T lymphocytes. B 
cells constitute part of the humoral-mediated response which specializes in the recognition and 
elimination of the extracellular pathogens, while T cells generate cell-mediated immune 
responses which target the intracellular pathogens. B lymphocyte maturation takes place within 
the bone marrow and is accompanied by the acquisition of a unique antigen-binding receptor on 
their surface, called the B cell receptor (BCR); the BCR constitutes a membrane-bound antibody. 
Upon antigen encounter, B cells differentiate into memory and effector cells, called plasma cells; 
the latter produce antibodies in a secreted form. 
T lymphocytes also arise in the BM but, subsequently, migrate to the thymus for their 
maturation. During their maturation, T cells express a unique antigen binding molecule, the T cell 
receptor (TCR). Both the BCR and TCR are products of somatic gene rearrangement during 
maturation. The genes encoding these receptors are assembled from variable and constant 
fragments through recombination activation gene (RAG) protein-mediated somatic 
recombination. However, the TCR in contrast to the BCR can only recognize antigen bound to 
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MHC molecules. T cells are distinguished by the presence of either CD4 or CD8 membrane 
glycoproteins on their surface. The CD4+ T cells recognize antigens in the context of MHC class 
II molecules on the surface of antigen-presenting cells, while the CD8+ T cells recognize antigens 
presented by MHC class I molecules found on all cells of a healthy individual. After a CD4+ T 
cell recognizes and interacts with a MHC class II-peptide complex, it is activated and secretes 
various cytokines, which play an important role in activating other immune cells, as B cells, 
CD8+ T cells, macrophages, etc. Thus, CD4+ T cells play a central role in both humoral and cell-
mediated immunity. CD8+ T cells exhibit high cytotoxic activity upon activation and act on 
eliminating potentially dangerous cells, like virus-infected cells, tumor cells or cells of a foreign 
tissue graft. 
Besides the conventional B and T cells, adaptive immunity encompasses the so-called 
innate-like lymphocytes, i.e. the B1 cells, the marginal-zone B cells, natural killer T (NKT) cells 
and subsets of γδ T cells; the diversity of antigen receptors expressed by these cells is restricted 
and not entirely random and their specificities are skewed towards a predefined set of ligands 124. 
In certain individuals, the discrimination of self from non-self malfunctions, leading to an 
immune attack upon the host, a condition termed as autoimmunity. During an autoimmune 
response, self-reactive clones of B or T cells are activated, generating humoral or cell-mediated 
responses against self-antigens. Normal healthy individuals are believed to possess self-reactive 
lymphocytes 125,126. However, since the presence of these cells does not necessarily lead to 
autoimmunity, mechanisms which regulate their activity exist. 
 
3.1.3.1 Mechanisms of T cell tolerance 
Random rearrangement of the TCR genes generates an enormous TCR repertoire, leading to 
specificities which in theory could also recognize soluble antigens, self antigens or antigens 
presented in non-self MHC molecules. Positive selection of T cells in the thymus ensures that 
TCR expressed on mature T cells will bind only to self MHC molecules; the T cells that fail to do 
so are eliminated by apoptosis. In a second step termed negative selection, T cells bearing a high-
affinity receptor for self antigens presented in self MHC are also eliminated. This selection 
procedure leads to the apoptosis of ~98% of all T cells in the thymus and ensures the generation 
of T cells, which are self-MHC restricted and self-tolerant. B cell progenitors undergo a similar 
process in the BM. This control of self-responsiveness that occurs during lymphocyte 
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development in the central lymphoid organs is known as central tolerance 127. One constraint of 
central tolerance is the requirement for the autoantigens to be present in the thymus. Although 
many tissue-specific antigens are represented in the thymus, at least at the mRNA level 128, 
whether or not they are expressed as proteins at levels sufficient to induce T cell deletion is not 
clear. In fact, healthy individuals have been shown to harbor self-reactive T cells in the periphery 
125,126 and these T cells are more likely to bear a low-affinity TCR for self-antigens 129. 
Mechanisms of peripheral tolerance protect us from these escaping self-reactive clones. 
In the periphery, recognition of a peptide−MHC complex on an APC can result either in 
the activation and clonal expansion of the T cell or in some cases in a state of non-responsiveness 
called anergy. In contrast to central tolerance, anergy does not lead to the apoptosis of the T cell 
but allows its survival in the periphery for an extensive period of time in a hyporesponsive state. 
Whether a T cell will be activated or subjected to anergy in the presence of peptide-MHC 
complex is determined by the presence or absence of sufficient co-stimulatory signals, delivered 
through the CD28-B7-1/2 interaction 130, or the ligation of ligands like the cytotoxic T 
lymphocyte associated antigen 4 (CTLA-4), a homologue of CD28 with inhibitory function 131. 
Dendritic cells (DC) have emerged as key APC in this process, regulating immunity versus 
tolerance. In fact, immature DC have been described to inhibit T cell responses, and are thus 
characterized as tolerogenic DC 132. This second level of control which regulates the 
responsiveness of mature lymphocytes against unwanted responses to self in the periphery is 
known as peripheral tolerance 133,134. 
In addition to the mechanisms of clonal deletion and anergy that physically eliminate or 
functionally inactivate potentially hazardous self-reactive lymphocytes, other mechanisms of 
tolerance include T cell ignorance of self antigens and the phenotype skewing. T cell ignorance 
occurs either because the antigen is expressed in sites not easily accessible to T cells or because 
the amount of antigen does not reach the threshold required to trigger a T cell response 135. In the 
phenotype skewing, effective tolerance might be maintained, even in the presence of an active 
immune response, depending on the nature of the response. Th2 cytokines, in particular, have 
been linked with downregulation of autoimmunity in experimental autoimmune 
encephalomyelitis 136 and diabetes 137. 
Finally, there is accumulating evidence that a subset of CD4+ T cells, named regulatory T 
cells, actively suppresses the activation and expansion of self-reactive T cells, thereby preventing 
autoimmune diseases 138-140. 
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3.1.3.2 Regulatory T cells 
Naturally occurring regulatory T cells (Treg) constitute 5-10% of all CD4+ T cells and 
possess potent ability to suppress immune cell effector functions in in vitro functional assays. 
They are present in the normal thymus, as a functionally mature and distinct T cell subpopulation 
141,142. Thus, Treg are already specialized for suppressive function before antigen encounter. This 
differentiates them from other types of regulatory T cells, such as Tr1 and Th3 cells, which under 
certain conditions arise in the periphery from naïve T cells following antigen exposure; these are 
termed induced Treg (iTreg), in contrast to the naturally occurring Treg (nTreg), which arise 
from the thymus 143,144. The TCR repertoire of Treg is broad and more diverse than the one of the 
naïve T cells, however, more self-reactive than other T cells 145,146. They appear to either escape 
thymic deletion or may indeed be positively selected as part of an ‘anti-self’ repertoire. This may 
explain why some Treg are in a more proliferative state than other T cells in the periphery of 
normal animals, presumably due to the recognition of self-antigens 147. Treg do not produce pro-
inflammatory cytokines upon antigenic stimulation and therefore do not harm the host, despite 
their high self-reactivity 148,149. Naturally occurring Treg are widely believed to exert their 
suppressive effect in a contact-dependent manner, in contrast to induced Treg which exert their 
suppressive function via cytokines, despite the fact that controversy has emerged from in vivo 
data, where in various models nTreg were shown to act through cytokine-dependent manner 150-
152. 
 
3.1.3.2.1 Phenotypic characterization of Treg 
Treg are characterized by the expression of cell surface markers, which are usually also found on 
activated T cells, like the α chain of the IL-2R (CD25), the glucocorticoid-induced TNF-receptor 
family-related gene/protein (GITR) and the cytotoxic T-lymphocyte-associated antigen-4 
(CTLA-4, CD152). Currently, the most specific and reliable molecular marker for the 
identification of Treg in rodents and humans is the transcription factor Foxp3, which is expressed 
in a highly Treg-specific manner and controls the development and function of Treg 153-155. 
Although Foxp3 expression is more restricted to CD4+ Treg identified in mice, human Foxp3 
expression is not as restricted as the mouse counterpart; several reports document its expression 
in effector T cells upon activation, although at a relatively lower level when compared to Treg 156-
162. Retroviral transduction of mouse Foxp3 to mouse CD4+CD25- T cells can convert them to 
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Treg-like cells, both phenotypically and functionally 153,154. Surprisingly, when human Foxp3 
and/or Foxp3δ2, an isoform of Foxp3 present on human Treg, are ectopically overexpressed in 
human CD4+ T cells, it does not lead to the acquisition of significant suppressor activity in vitro 
163, suggesting that the mouse and human Foxp3 may have some differences. 
The gene foxp3 was identified as the defective gene in the Scurfy mouse strain, which has 
a X-linked recessive mutation leading to lethality in hemizygous males or homozygous females 
within a month after birth 164. Mutations of the human gene FOXP3, the ortholog of the murine 
foxp3 gene, were subsequently found to be the cause of the Immune dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked immunodeficiency (IPEX) syndrome, which leads to 
the development of organ-specific autoimmune diseases, inflammatory bowel disease (IBD), 
allergic dermatitis, food allergy, hematological disorders, hyperimmunoglobulinemia E, and 
serious infections 165,166. Although IPEX is a rare disease, its clinical picture and its causative 
factor as a deficiency or malfunction of Treg underlies the role of Treg in maintaining 
immunologic self-tolerance. 
Recent analysis of Foxp3-reporter mice and intracellular staining of the Foxp3 protein 
revealed a correlation between the ontogeny of CD25-expressing Treg and Foxp3-expressing T 
cells 167. This analysis confirmed the finding that natural Treg become detectable in the periphery 
of normal mice a few days after birth and thymectomy around day 3 after birth abrogates the 
thymic production of natural Treg from the beginning of their ontogeny 168. There is substantial 
evidence that CD25 is not a mere indicator of the chronically activated state of Treg, but is a 
functionally essential molecule for their survival and function. For example, IL-2, IL-2Rα 
(CD25) and IL-2Rβ (CD122) deficiencies produce similar fatal lymphoproliferative 
inflammatory disease, as the Foxp3 deficiency, with autoimmune components, generally 
characterized as ‘IL-2 deficiency syndrome’ 169-173; while deficiency of the common γ chain 
completely abrogates the development of the other T cells as well. In addition, neutralization of 
circulating IL-2 resulted in selective reduction of CD4+CD25+Foxp3+ T cells in the thymus and 
periphery. These findings collectively indicate that the IL-2 and transcription factor Foxp3 are 
key control molecules for the development and function of natural CD4+CD25+ Treg. Since 
Foxp3 is a nuclear factor, the combination of CD4 and CD25 markers have been more commonly 
used for the isolation or depletion of Treg. 
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3.1.3.2.2 Treg and autoimmunity 
Treg play an indispensable role in the mechanism of self-tolerance, since depletion of these cells 
from normal animals by the use of a mAb directed against CD25 leads to the spontaneous 
development of various autoimmune diseases, such as autoimmune gastritis, thyroiditis, type I 
diabetes (TID) and IBD; reconstitution of the animals with normal CD4+CD25+ T cells prevents 
these disorders 174,175. In addition, the incidence of autoimmune disease in IPEX patients, which 
have a mutated Foxp3 gene, is approximately 90%, with approximately 80% incidence of TID 
within a year after birth 176. Some patients, in fact, already manifest the disease at the time of 
birth 176. The high incidence of autoimmune disease in IPEX patients suggests that most of 
normal individuals may harbor potentially pathogenic self-reactive T cell clones, capable of 
mediating common autoimmune diseases. This is an indication that dominant self-tolerance is 
physiologically operating in humans as well as rodents with the purpose of preventing 
autoimmune disease. 
Treg not only inhibit autoimmune responses but also suppress a variety of immune 
responses to non-self antigens. Depletion of CD4+CD25+ T cells from animals enhances immune 
responses to microbes, triggers allergic responses and breaks feto-maternal tolerance during 
pregnancy. In addition, depletion of Treg provokes effective tumor immunity to autologous 
tumor cells in otherwise nonresponding animals 138. Conversely, natural Treg can be exploited to 
treat autoimmune diseases and to establish immunologic tolerance to non-self antigens as in 
organ transplantation. 
 
3.1.3.2.3 Treg and tumor immunity 
Although Treg play a crucial role in preventing autoimmunity by inducing immune tolerance, 
they might inhibit anti-tumor immunity and promote tumor growth by suppressing host immune 
responses against non-self antigens. Sakaguchi and colleagues first demonstrated that the removal 
of CD4+CD25+ T cells can induce antitumor responses, establishing a ‘common basis’ between 
tumor immunity and autoimmunity 177. In later studies, many groups reported elevated 
percentages of CD4+CD25+ Treg in the total T cell population isolated from tumor tissues or 
peripheral blood in a variety of cancers, including lung cancer 178, breast cancer 179, ovarian 
cancer 180, melanoma 181, liver cancer 182, gastric cancer 183 and lymphoma 184. From these 
studies, two are of a particular interest. Curiel et al. reported that Treg preferentially accumulate 
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in ovarian tumors and in malignant ascites attracted by CCL22 and that the high percentage of 
Treg is associated with the poor prognosis of cancer patients 180. This study suggests that Treg 
may mostly interfere with the function of effector T cells and not so much with their priming 
phase. Viguier at al., on the other hand, found higher accumulation of Treg in the draining lymph 
nodes infiltrated by melanoma cells, suggesting that Treg contribute to the local 
immunosuppressive milieu 181. Increasing number of evidence indicates that Treg in the tumor 
microenvironment inhibit anti-tumor immunity, which represents a major obstacle for developing 
effective therapeutic cancer vaccines. 
 
3.1.3.2.4 Treg and innate immunity 
The suppressive effect of Treg on the adaptive responses mediated by T cells is well documented. 
However, the effect of Treg on cells of the innate immune system is less well studied. A potential 
role for Treg in dampening NK cell functions was first suggested by Sakaguchi in a murine 
leukemia model 177. More recently, it was reported that Treg depletion in vivo led to the rejection 
of NK cell sensitive cell lines expressing RAE-1, the ligand for the activating receptor NKG2D 
69,70 in vivo 185,186. In vitro, NK cell cytotoxicity was largely inhibited by Treg through a TGF-β-
dependent and IL-10-independent mechanism 185,186. These studies suggest that Treg directly 
inhibit NK cell activation towards NKG2D ligand-expressing targets in vitro and in vivo. In 
another recent study, Treg could induce NK cell death in a granzyme B- and perforin-dependent 
manner 187. In a model of hybrid resistance during allogeneic BM transplantation, Treg removal 
significantly enhanced NK cell-mediated BM graft rejection 188. 
It has been proposed that Treg can directly suppress monocyte/macrophage activation and 
their effector functions in vitro. Pre-incubation of human blood monocytes with Treg or the 
presence of Treg in the monocyte culture impaired cytokine production 189,190 and the 
upregulation of HLA II, CD40 and CD80 activation markers by monocytes upon LPS stimulation 
190. Kryczek et al. reported upregulation of the inhibitory molecule B7-H4 on isolated human 
monocytes mediated by Treg 191. In addition, B7-H4 expression on macrophages infiltrating 
ovarian tumors inversely correlated with the patients’ survival 192. The ability of Treg to steer 
monocyte differentiation towards an alternative activated phenotype, marked by an upregulation 
of CD206 and CD163 markers, was also demonstrated in vitro 193. In addition to macrophages, 
one study provided data that Treg could inhibit reactive oxygen intermediates and cytokine 
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production by neutrophils, although this phenomenon was only observed after in vitro treatment 
of both Treg and neutrophils with LPS 194. Finally, in a model of acute in vivo ablation of Treg, it 
was observed that various types of innate immune cells, including NK1.1+ cells and macrophages 
(F4/80+CD11c- cells) increased in numbers in the secondary lymphoid organs after Treg ablation 
195. Nevertheless, it is possible that Treg do not exert their suppressive effect on innate immune 
cells via direct interaction but in an indirect manner as visualized for T cells. Treg inhibited the 
activation of autoreactive T cells in the LN by impeding the formation of stable contacts between 
T cells and DC 196,197. 
 
3.1.3.2.5 Manipulation of the suppressive function of Treg 
Given the observations that Treg exercise a negative role in tumor immunity, a key question in 
cancer immunotherapy is how to eliminate or to reverse the suppressive function of Treg. 
Cyclophosphamide is a chemotheurapeutic agent with anti-mitotic action, used to treat various 
types of cancer. High doses of this drug lead to immunosuppression, the basis of other clinical 
uses, as preventing organ rejection in organ transplantation 198,199. Low doses of this drug, 
however, lead to enhanced immune responses against a variety of antigens 200,201. The 
chemotherapeutic activity of cyclophosphamide was readily linked with the elimination of tumor-
induced suppressor T cells 202,203 and later, namely, with its effect on Treg. Controversy still 
exists, however, on whether cyclophosphamide solely decreases Treg cell numbers 204, interferes 
with their suppressive function 205 or influences both numbers and suppressive ability 206, and on 
the mechanism of action. Another approach used in clinical studies is the administration of an 
anti-CTLA-4 mAb; however, the antitumor effects of CTLA-4 blockade were shown to be due to 
increased T cell activation rather than inhibition or depletion of the CTLA-4-expressing Treg 
207,208. Presently, several investigators are targeting the specific elimination of Treg with a fusion 
protein of diphtheria toxin and the IL-2 cytokine (ONTAK, Denileukin diftitox, DAB389IL-2). 
Administration of ONTAK could efficiently eliminate CD25-expressing Treg and yielded 
effector functions in patients with melanoma or renal cancer 209,210. Another recombinant 
immunotoxin, LMB-2, has been used for the same purpose. LMB-2 is a fusion of a single-chain 
Fv fragment of the CD25-specific, anti-Tac mAb to a truncated form of the bacterial 
Pseudomonas exotoxin A, which has been shown to selectively eliminate human Treg in vitro 
without impairing the function of the remaining lymphocytes 211. In vivo, the administration of 
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this toxin in metastatic melanoma patients before vaccination led to a transient reduction in 
circulating Treg numbers without augmenting, however, the efficiency of the vaccination 212. 
 An alternative approach to Treg depletion in vivo is to reverse the suppressive function of 
Treg. It has been demonstrated that TLR signaling activation on DC can render naïve T cells 
refractory to suppression mediated by Treg in mice 213. In humans, Poly-G oligonucleotides, 
which are recognized by TLR8, can directly reverse the suppressive effect of Treg in the absence 
of DC 214. Poly-G oligonucleotides could not reverse the suppressive activity of murine Treg 215, 
because TLR8 is not functional in mice. In addition, activation of TLR2 with its ligand Pam3Cys 
directly increased the proliferation of murine Treg and temporally reversed their suppressive 
function 216,217. Other TLR ligands, however, fail to do so. Human TLR5, for example, enhanced 
rather than reversed the suppressive function of Treg 218.  Further studies are needed to define the 
role of other TLR on the function of mouse and human Treg and effector cells. 
 
 
3.2 Type I IFN 
Type I IFN are a family of glycoproteins which includes several members, namely IFN-α, 
IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ, IFN-ω and IFN-ζ, also known as limitin 219. All the 
members bind to the same receptor complex known as the IFN-α receptor (IFNAR), which 
constitutes of two subunits, the IFNAR1 and the IFNAR2 220. 13 isoforms have been described 
for IFN-α, and one for IFN-β, -ε, -κ, -τ and -ζ; although IFN-ω has only one functional form, 
several pseudogenes have been identified. Type I IFN and IFN-induced proteins have a crucial 
role in the defense against viruses and are unique in vertebrates. They are produced in response to 
viral infections by many cell types, including lymphocytes, macrophages, fibroblasts, endothelial 
cells, osteoblasts etc. These proteins trigger the expression of more than 100 genes, the products 
of which have diverse antiviral activities 221. Type I IFN can be induced early during infection, 
and can thus activate promptly the cells of the innate immune system such as NK cells and 
macrophages 222.  
In principle, all virally infected cells can produce type I IFN, resulting in autocrine and 
paracrine IFN-mediated signaling, which confers an antiviral state on the infected and 
neighboring cells. Type I IFN production has been originally studied in virus-infected fibroblasts, 
where the role of IRF-3 and IRF-7 has been demonstrated 223,224. Both of these factors reside in 
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the cytoplasm and require phosphorylation in their C-terminal region for their activation and 
translocation to the nucleus, where they activate their target genes. In vivo observations further 
supported the importance of these factors. Irf3-/- mice are vulnerable to encephalomyocarditis 
virus (EMCV) infection 225. Subsequent generation of the Irf7-/- mice showed that these mice are 
more susceptible to infections of both DNA and RNA viruses, such as Herpes simplex virus 
(HSV)-1 and EMCV, than wt or Irf3-/- mice, establishing IRF-7 as a master regulator of type I 
IFN-mediated immune responses 225. The IRF-7-dependent pathway is often referred to as the 
classical pathway of IFN gene induction. 
Alternatively, type I IFN production can be elicited in response to viral or bacterial 
nucleic acids by the engagement of TLR, namely TLR3, TLR7/TLR8 and TLR9. These receptors 
detect viral double-stranded RNA, single stranded RNA or unmethylated CpG motifs present in 
microbial DNA, respectively 226,227. An exception to this rule seems to be the IFN-β production in 
response to TLR4 ligands, which are not nucleic acids 7. TLR4 is activated by LPS or the lipid A 
component of Gram-negative bacteria, as well as some viral components 228. Plasmacytoid DC 
(pDC) can produce systemic levels of IFN-α after engagement of TLR and thus are often referred 
to as specialized type I IFN producing cells 229.  
 
3.2.1 Regulatory effects of type I IFN 
Although first characterized based on their potent antiviral functions, type I IFN can also 
mediate a variety of immunoregulatory effects, suggesting that they can be important links 
between innate and adaptive immune responses. First of all, it has been shown that type I IFN can 
regulate their own expression. Particular IFN genes, namely IFN-β and/or IFN-α4, are first 
induced in virally infected cells; the products of their target genes can then act on the neighboring 
cells to induce the expression of other IFN-α subtypes 224,230. The most well known effect of type 
I IFN is the enhancement of antigen processing and antigen presentation via the MHC class I 
pathway, leading thus to an enhancement of CD8+ T cell-mediated responses 231. Type I IFN 
contribute to the maturation of DC and the induction of co-stimulatory molecules 232,233. Type I 
IFN have been proposed to induce the expression of IL-15 234, which has been linked with the 
enhanced NK cell and memory CD8+ T cell proliferation early during viral infections 222,235. In 
contrast, type I IFN have been shown to negatively regulate the expression of IL-12 in mice both 
in vitro and in vivo during infection with MCMV 236 and in human in vitro generated DC co-
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cultured with CD4+ T cells 237. Since IL-12 is a potent stimulator of IFN-γ production, type I IFN 
can control the subsequent immune response. Interestingly, IFN-γ production was enhanced by 
type I IFN in a IL-12-independent manner during a LCMV infection 238. 
Type I IFN or chemical type I IFN inducers, i.e. tilerone, or analogues of viral nucleic 
acids such as polyinosinic-polycytidylic acid [poly(I:C)] were shown to enhance NK cell 
cytotoxicity and their in vivo trafficking 239-241. Only recently, however, it was clearly 
demonstrated – with the use of an in vivo mouse model of inducible depletion of DC – that type I 
IFN do not directly activate NK cells but rather indirectly via DC, which in turn produced and 
trans-presented IL-15 to NK cells in vivo 87. Finally, in addition to their regulatory effects, type I 
IFN affect the development and homeostasis of B and T cells, DC and osteoclasts 242-244. 
 
3.2.2 Type I IFN and tumor 
In addition to their antiviral activity, exogenously administered type I IFN have been shown to 
suppress the growth of transplantable tumors of different origins as well as pulmonary metastases 
in mice 245-247. Type I IFN could have a direct inhibition on tumor cell proliferation in vitro by 
promoting cell growth arrest in the G1 and S phases 248,249. In addition, type I IFN treatment 
resulted in vascular endothelial cell damage that preceded tumor necrosis 250 and restored the 
levels of other tumor-promoting factors, such as down-regulating matrix metalloproteinase 
(MMP)-9 and up-regulating E-cadherin 251. For these reasons, exogenously administered type I 
IFN have also been used in clinical applications for the treatment of a range of malignancies such 
as hairy cell leukemia, melanoma, renal cell carcinoma and Kaposi sarcoma 252. Nevertheless, 
clinical success has been limited due to the short half-life of type I IFN, which is less than 5h, and 
the side effects from the high dose administration required for effective therapy 253,254. 
Besides the well documented role of type I IFN administration for tumor treatment, there are 
few reports documenting a role for endogenous type I IFN in the control of tumor growth of 
transplantable tumors 255-257. Although much progress has been made in understanding the 
mechanisms of type I IFN responses to infection and inflammation, it is less clear how type I IFN 
production is stimulated during an anti-tumor response, which cells produce them, which cells 
respond to them and what is the importance of type I IFN for anti-tumor immunity. 
Recently, a role for type I IFN in tumor immunoediting has been described 258; MCA-
induced sarcomas arising in IFNAR1-/- mice exhibited an unedited phenotype, i.e. they were 
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immunogenic and were rejected in a T cell-dependent manner when transplanted into wt 
recipients. In addition, type I IFN have been shown to control NK cell-mediated anti-tumor 
responses against MCA-induced sarcomas, MHC class I deficient RMA-S tumors and cytokine 
immunotherapy of lung metastases 259. Interestingly, a role for IFN-α in downregulating the 
recognition of tumor cells by NK cells has also been proposed by the inhibition of the expression 
of H60 and, to a lesser extent, of MULT1 on MCA-induced sarcoma lines from 129/Sv mice after 
in vitro culture with IFN-α  260. 
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4 AIM OF THE STUDY 
 
In cancer patients, many tumors downregulate expression of MHC class I molecules in order to 
escape direct recognition by CD8+ T cells, which is MHC class I restricted 261. At the same time, 
these tumors become more susceptible to NK cell attack due to the lack of self MHC class I 63. 
However, upon inoculation of higher tumor cell numbers, tumors escape the control of the 
immune system. Therefore, it is essential to define mechanisms to strengthen the immune 
response against a high tumor cell load and tumors with poor immunogenicity. Strategies to 
enhance anti-tumor immune responses include activation of anti-tumor effector functions via the 
administration, for example, of cytokines 262,263 or, on the other hand, the removal of suppressive 
signals counteracting activation. 
In this regard, the aim of our study is to strengthen the immune response against a MHC 
class I-deficient tumor, the RMA-S lymphoma. For this purpose, the role of immunosuppressive 
Treg in inhibiting innate immune cell functions during the anti-tumor response in vivo is 
addressed. In order to achieve this, we experimentally remove Treg before s.c. inoculation of 
mice with RMA-S tumor cells and analyze the emerging anti-tumor effector functions. 
The second part of this study deals with the role of type I IFN in the anti-tumor immunity 
against the RMA-S lymphoma. Type I IFN have been well characterized for their contribution in 
anti-viral responses 264. In parallel, they have been extensively used in clinical practice to treat 
various types of cancers 265. Few reports exist, however, documenting the production of type I 
IFN during an anti-tumor response as well as their contribution to the control of tumor growth. In 
order to pinpoint the role of type I IFN in the anti-tumor response, we are monitoring the growth 
of RMA-S lymphoma in mice unresponsive to type I IFN (IFNAR1-/- mice), and characterizing 
the anti-tumor mechanisms which are under their control. 
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5 MATERIALS AND METHODS 
5.1 MATERIALS 
5.1.1 Laboratory equipment 
(listed in alphabetical order) 
Equipment Company 
Anesthesia machine, Vapor 19.1 Drägerwerk AG 
Beta-counter, MicroBeta TriLux 1450 LSC PerkinElmer 
Bio-plex array system Bio-rad 
Cell culture incubator, Heraeus BBD 6220 (CO2 ) Kendro 
Centrifuge, Heraeus Multifuge 4 K-R/3 S-R Kendro 
Centrifuge 5415 R (table) Eppendorf 
Centrifuge, Sorvall Evolution RC Kendro 
ELISA microplate reader, GENios TECAN 
FACS sorter, FACSDiva  BD 
FACS sorter, FACSVantage SE BD 
Flow cytometer, FACSCalibur BD 
Flow hood, Heraeus Hera Safe Kendro 
Fridge, premium Liebherr 
Freezer -20°C, comfort/profi line Liebherr 
Freezer -86°C, VIP series Sanyo 
Gamma-counter, Cobra auto-gamma Packard, PerkinElmer 
Gamma cell 1000 Atomic Energy of Canada Ltd 
Harvester 96-well automated, TOMTEC PerkinElmer 
Heat sealer PerkinElmer 
Ice machine Hoshizaki 
Incubator Shaker, Innova 4200 New Brunswick Scientific 
Magnetic stirrer, MR3001 K Heidolph 
Microscope, WILOWERT30 Neolab 
Microscope (Stereo Microscope) Hund 
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Microscope C1Si (confocal) Nikon 
Minifuge, GalaxyMini VWR 
N2 tank, CryoSystem 6000 MVE 
pH meter WTW 
Photometer, Ultraspec 3100 Amersham Biosciences 
Pump, Econo Pump Bio-Rad 
Rotating wheel Labor-Brand 
Scales, PB602-S  Heidolph 
Scales (micro), AG285 Heidolph 
Vortex, VortexGenie2 VWR/Scientific Industries 
Water bath, Heraeus Julabo TW20 Kendro 
 
5.1.2 Cell culture products 
Product Source Cat. No. 
Standard tissue culture flasks/filter screw caps – 25 
cm2 
TPP 90026 
Standard tissue culture flasks/filter screw caps – 75 
cm2 
TPP 90076 
Standard tissue culture flasks/filter screw caps – 150 
cm2 
TPP 90151 
Tissue culture flasks/filter screw caps – 182 cm2 Greiner 660175 
96-well U-bottom with lid – Standard TC BD 353077 
96-well flat-bottom with lid – Standard TC BD 353072 
96-well flat-bottom with transwell insert Corning 3381 
48-well flat-bottom with lid – Standard TC BD 353078 
24-well flat-bottom with lid – Standard TC BD 353047 
12-well flat-bottom with lid – Standard TC BD 353043 
6-well flat-bottom with lid – Standard TC BD 353046 
50ml conical tubes Falcon™ BD 352070 
15ml conical tubes Greiner 188271 
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5 ml round-bottom polypropylene test tube BD 352008 
5 ml round-bottom polystyrene test tube with cell 
strainer 
BD 352235 
0,6 ml  round-bottom test tube Greiner 101101 
Eppendorf tubes   
70 µm cell strainer Falcon™ BD 352350 
40 µm cell strainer Falcon™ BD 352340 
Cryovial®, 2ml sterile Roth E309.1 
NalgeneTM Cryo 1°C Freezing Container, “Mr. Frosty” Nunc 5100-0001 
35mm FluoroDish™ WPI FD35-100 
HiTrap Protein G HP, 5ml GE Healthcare 17-0405-01 
 
5.1.3 Cell culture media 
Product Source Cat. No. 
RPMI 1640 (1x) w/o L-Glutamine GIBCO-Invitrogen 31870 
D-MEM (1x) (High Glucose) with L-Glutamine, 4500 
mg/L D-Glucose, w/o sodium pyruvate 
GIBCO-Invitrogen 41965 
D-PBS (1x) w/o Ca, Mg, sodium bicarbonate GIBCO-Invitrogen 14190 
IMDM Iscoves Modified Dulbecco Medium (1x) GIBCO-Invitrogen 21980032 
Fetal Bovine Serum, Origin: EU Approved GIBCO-Invitrogen 10270 
Penicillin/Streptomycin-Solution 
10000 U/ml penicillin, 10000 µg/ml streptomycin 
GIBCO-Invitrogen 15140 
L-Glutamine 200 mM (100x), 29.2 mg/ml GIBCO-Invitrogen 25030 
Non-essential amino acids (100X) GIBCO-Invitrogen 11140035 
Sodium pyruvate MEM 100mM GIBCO-Invitrogen 11360088 
β-mercaproethanol 50mM GIBCO-Invitrogen 31350010 
Trypsin –EDTA (1x) HBSS w/o Ca2+/Mg2+ w/ EDTA GIBCO-Invitrogen 25300 
Dimethylsulphoxide Hybri Max® (DMSO) Sigma-Aldrich D2650 
Cell Dissociation Solution Non-enzymatic 1x Sigma-Aldrich C5914 
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5.1.4 Solutions 
(listed in alphabetical order) 
 
ACK lysis buffer   0.829 g NH4Cl 
     0.1 g  KHCO3 
     0.38 mg EDTA 
     100 ml  ddH2O 
       pH 7.3 
 
FACS buffer     1x  PBS 
     0.02 % (v/v) NaN3 in PBS 
     1%   FCS 
     0.5 mM EDTA 
 
Freezing medium   1x  FCS 
     10%  DMSO 
 
MACS buffer    1x  PBS 
     1%   FCS 
     0.5 mM EDTA 
 
Primary cell culture medium  1x  RPMI 
     10%  FCS 
     2 mM  L-glutamine 
     100 U/ml  Penicillin 
100 µg/ml Streptomycin 
     1 mM  Sodium Pyruvate 
     1x  Non-essential amino acids 
     0.25 mM β-mercaptoethanol 
 
PBS (10x)    1.37 M  NaCl 
     27 mM  KCl 
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     100 mM Na2HPO4 (anhydrous) 
20 mM  KH2PO4 
 
Antibody purification: 
Binding buffer    20 mM  Sodium phosphate 
       ddH2O 
       pH 7.0 
 
Elution buffer    0.1 M  Glycin HCl 
       ddH2O 
       pH 2.7 
 
Neutralization buffer   1 M  Tris-HCl 
       ddH2O 
       pH 9 
 
Precipitation buffer   29.1 g  (NH4)2SO4 
     100 ml  ddH2O 
 
5.1.5 Chemicals 
(listed in alphabetical order) 
Product Source Cat. No. 
1-methyl- L -tryptophan (1MT) Sigma-Aldrich 860646 
Brefeldin A Sigma-Fluka B7651 
Carboxyfluorescein succinimidyl ester (CFSE) Sigma-Fluka 21888 
Chromium-51 PerkinElmer NEZ030005MC 
Collagenase, type IV from Clostridium histolyticum Cell systems LS004188 
DNAse I Sigma DN25-1G 
FACS lysing solution (10x) BD 349202 
Heparin-Sodium, 25 000 Units B Braun 1708.00.00 
IFN-γ,  recombinant mouse BD 51-9000889 
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Indomethacin Sigma-Fluka 57413 
Isofluoran B Braun 6724123.00.00 
Lipopolysaccharide (LPS) Sigma-Fluka L4391 
Lycopersicum esculentum lectin Vector Labs FL-1171 
[methyl-3H] Thymidine Amersham TRK637-5MCI 
NG-Monomethyl-D-arginine monoacetate Alexis ALX-106-002 
NG-Monomethyl-L-arginine monoacetate Alexis ALX-106-001 
PMSF Applichem A0999 
Paraformaldenhyde (PFA) Applichem A3813 
Propidium Iodide (PI) Sigma-Fluka 70335-5ML-F 
TNFa, recombinant human Kindly provided by Dr. Rüdiger Arnold, 
DKFZ 
TRAIL,  recombinant mouse Biomol SE-722 
Triton X-100 Sigma-Fluka T9284 
Saponin from quillaja bark Sigma S4521 
 
5.1.6 Antibodies 
5.1.6.1 Antibodies for FACS analysis 
The following antibodies against mouse antigens were used (listed in alphabetical order): 
Ab specificity Conjugate Clone Isotype Dilution Source Cat. No. 
B7-H4 PE 188 rat IgG2a, κ 1:100 eBioscience 12-5972 
CD3 FITC 145-2C11 armenian 
hamster 
1:100 BD 553062 
CD3 APC 145-2C11 armenian 
hamster 
IgG, κ 
1:100 BD 553066 
CD4 FITC GK1.5 rat IgG2a 1:100 BD 553046 
CD4 PECy5 H129.19 rat IgG2a 1:100 BD 553654 
CD8 PE 53-6.7 rat IgG2a, κ 1:100 BD 553033 
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CD11b FITC M1/70 rat IgG2b 1:100 BD 557396 
CD11b APC M1/70 rat IgG2b 1:100 BD 553312 
CD11c FITC HL3 hamster 
IgG1 
1:100 BD 557400 
CD25 FITC 7D4 rat IgM 1:100 BD 553071 
CD25 PE PC61 rat IgG1 1:100 BD 553866 
CD45.1 FITC A20 mouse 
IgG2a 
1:1000 BD 553775 
CD45.1 PE A20 mouse 
IgG2a 
1:100 BD 553776 
CD80 (B7-1) PE 16-10A1 rat IgG2a, κ 1:100 BD 553692 
CD86 (B7-2) PE GL1 rat IgG2a, κ 1:100 BD 553692 
CD95 FITC Jo2 armenian 
hamster 
IgG2, λ 
1:20 BD 554257 
CD119  
(IFN-γR, a chain) 
biotin GR20 rat IgG1 1:100 BD 558771 
CD273 (B7-DC) PE TY25 rat IgG2a, κ 1:100 BD 557796 
CD274 (B7-H1) PE MIH5 rat IgG2, λ 1:100 BD 558091 
CD275 (B7-H2) PE HK5.3 rat IgG2a, κ 1:100 eBioscience 12-5985 
CD276 (B7-H3) PE M3.2D7 rat IgG2a 1:100 eBioscience 12-5973 
F4/80 Alexa488 BM8 rat IgG2a 1:100 Caltag MF48020 
Foxp3 PE FJK-16s rat IgG2a 1:100 eBioscience 12-5773 
Gr-1 APC RB6-8C5 rat IgG2a 1:100 BD 553129 
H-2Kb PE AF6-88.5 mouse 
IgG2a, κ 





1:200 BD 553552 
IFN-γ FITC XMG1.2 rat IgG1 1:50 BD 554411 
Ly-6C/G (Gr-1) APC RB6-8C5 rat IgG2b 1:1500 BD 553129 
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NK1.1 PE PK136 mouse 
IgG2a 
1:1500 BD 557391 
Isotypes       
Isotype FITC R3-34 rat IgG1  BD 554684 
Isotype PE MOPC-21 mouse IgG1  BD 559320 
Isotype PE R35-95 rat IgG2a  BD 553930 
Isotype APC A95-1 rat IgG2b  BD 553991 
Streptavidin APC   1:1000 BD 554067 
 
5.1.6.2 Antibodies for in vitro activation 
The following antibody against mouse CD3 was used in vitro for the activation of T cells: 
Ab specificity Clone Isotype Source Cat. No. 
CD3 145-2C11 armenian hamster IgG1, κ BD  553057 
 
5.1.6.3 In vivo administered antibodies 
The following antibodies against mouse antigens were injected i.p. in mice for the depletion of 
cell populations or the neutralization of cytokines (listed in alphabetical order): 
Ab specificity Clone Isotype Source 
CD4 GK1.5 rat IgG2a Purification from hybridoma 
CD8 2.43 rat IgG2b Bioexpress 
CD25 PC61 rat IgG1 Purification from hybridoma 
CD95L MFL 4 armenian 
hamster IgG 
Kindly provided by Prof. Yagita, 
Juntendo University School of 
Medicine, Kyoto, Japan 
IFN-β 7FD3 rat IgG1 Purification from hybridoma 
IFN-γ XMG1.2 rat IgG1 Bioexpress 
IL-10R YL03.1B1.3a rat IgG1 DNAX 
NK1.1 PK136 mouse IgG2a Bioexpress 
TGF-β 1D11 mouse IgG1 Bioexpress 
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5.1.7 Cell lines 
The cell lines that were used in this study are listed below (in alphabetical order): 
Cell line Cell type Medium* Reference 
2.4G2 anti-CD16/CD32 hybridoma RPMI 1640 266 
7FD3 anti-IFN-β hybridoma RPMI 1640 Kindly provided 
by Dr. Rainer 
Zawatzky, 
DKFZ 
EC7.1 MHC class I-deficient variant of RMA-S IMDM 267 
Jurkat human T cell leukemia RPMI 1640 268 
L929 mouse fibroblast  DMEM 269 
PC61 anti-CD25 hybridoma RPMI 1640 270 
RMA mouse T cell lymphoma RPMI 1640 271 
RMA-S TAP2-deficient variant of RMA RPMI 1640 271 
RMA-RAE-1γ RAE-1γ transfectant of RMA RPMI 1640 69 
YAC-1 mouse lymphoma RPMI 1640 9 
 
*All media were supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin with the exception of PC61 which 
was supplemented with 5%  FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin, 1 mM sodium pyruvate and 0.25 mM ß-mercaptoethanol. 
 
Cell lines were regulary checked for mycoplasma contamination using PCR based assay. 
 
5.1.8 Magnetic Cell Sorting (MACS) beads and columns 
Product Source Cat. No. 
anti-CD4 beads Miltenyi Biotec 130-049-201 
anti-CD8 beads Miltenyi Biotec 130-049-401 
anti-CD11b beads Miltenyi Biotec 130-049-601 
anti-CD90 beads Miltenyi Biotec 130-049-101 
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anti-DX5 beads Miltenyi Biotec 130-052-501 
Regulatory T cell Isolation kit Miltenyi Biotec 130-091-041 
anti-APC beads Miltenyi Biotec 130-090-855 
MS Columns Miltenyi Biotec 130-042-201 
LS Columns Miltenyi Biotec 130-042-401 
LD Columns Miltenyi Biotec 130-042-901 
 
5.1.9 Kits 
Product Source Cat. No. 
PE anti-mouse/rat Foxp3 Staining Set eBioscience 72-5775 
Mouse IFN-γ OptEIATM Set BD 555138 
OptEIATM Reagent Set B BD 550534 
Mouse IFN-γ in vivo capture assay BD 558491 
Bio-plex cytokine reagent kit Biorad 171-304000 
Bio-plex cell lysis kit Biorad 171-304011 
Bio-Plex mouse serum diluent kit Biorad 171-305005 
Bio-plex mouse IFN-γ assay Biorad 171-G11934 
Bio-plex mouse IL-1β assay Biorad 171-G12819 
Bio-plex mouse IL-6 assay Biorad 171-G10738 
Bio-plex mouse IL-10 assay Biorad 171-G11356 
Bio-plex mouse IL-13 assay Biorad X60-000ZFYB 
Bio-plex mouse IL-12 (p70) assay Biorad 171-G13758 
Bio-plex mouse MIP-1α assay Biorad 171-G16477 
Bio-plex mouse MIP-1β assay Biorad X60-005KMTI 
Bio-plex mouse MIP-2 assay Biorad XD0-000001T 
Bio-plex mouse VEGF assay Biorad XD0-000007B 
BCATM Protein Assay kit Pierce 23227 
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5.2 MICE 
C57BL/6 wild-type (wt) and C57BL/6-Ly5.1 congenic mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany and Erembodegem, Belgium). C57BL/6-Ly5.1, IFNAR1-/- and 
RAG2-/-IFNAR1-/- mice were bred in our animal facility. IFN-γ receptor-/- (IFN-γR-/-), perforin-/- 
(Prf-/-) and inducible Nitric Oxide Synthase-/- (iNOS-/-) C57BL/6 mice were purchased from 
Jackson Laboratory (Bar Harbor, Maine, USA). Mice were housed in specific pathogen-free 
conditions and used in experiments at 6-8 wk of age. All experiments were performed according 





5.3.1 Cell culture methods 
 
5.3.1.1 Determination of cell number 
An aliquot of cell suspension was diluted 1:1 with trypan blue solution (0.05 % w/v) to 
distinguish dead cells and cells were counted with a Neubauer counting chamber (0.1 mm depth). 
The number of live cells per ml is calculated as following: 
average cell number / chamber square (0.1 mm3) x dilution factor x 104 
 
5.3.1.2 Freezing and thawing of cells 
For freezing of cells, cell suspensions were centrifuged (1200 rpm, 10 min, RT) and the pellet 
was resuspended in freezing medium at a concentration of 5 x 106 cells/ml. 2 ml aliquots in 
freezing tubes were placed in ice-cooled freezing containers and placed for 24 h at -80°C. Frozen 
cells were subsequently stored in liquid nitrogen. 
Cell thawing was performed quickly in a 37°C water bath until ~ 10% of suspension remained 
frozen. The suspension was immediately diluted into 9 ml of appropriate cold medium and 
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centrifuged (1200rpm, 10 min, RT). Cells were resuspended in medium and cultured at 37°C, 
5 % CO2. 
 
5.3.1.3 Splitting of adherent cells 
For the splitting of adherent cells, the culture medium was removed from the flasks, the cells 
were washed once with pre-warmed PBS, and Trypsin-EDTA or Cell Dissociation Solution was 
added in sufficient amount to cover the cell layer. Cells were then incubated at 37°C for ~5 min, 
checking in parallel the progress of detachment under the microscope. After complete 
detachment, culture medium was added to the flask, cells were collected in Falcon tubes and 
centrifuged (1200 rpm, 10 min, RT). Cells were subsequently splitted at the appropriate ratio into 
new flask or used in experiments. 
 
5.3.1.4 Splitting of suspension cells 
Cells in suspension reaching an optimal density were split in the appropriate ratio, ranging 
between 1:5 up to 1:20 by adding the appropriate volume of medium. 
 
5.3.2 Mouse tumor model 
For the analysis of tumor growth in vivo, tumor cell lines were harvested in the exponential 
growth phase. Tumor cells were washed 3 times with PBS and resuspended in PBS at a 
concentration of 1 x 107 cells/ml for RMA or RMA-S cells or 1 x 106 cells/ml, primary to 
injection. Groups of 5-10 mice were injected s.c. in the shaved left flank with 100 µl of tumor cell 
suspension. Tumor growth was assessed 3 times weekly with a caliper measuring along the 
perpendicular axes of the tumors and expressed as the product of the two diameters. For 
rechallenge experiments, mice were rested for at least 3 months after primary tumor cell 
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5.3.2.1 Isolation of organs and preparation of single cell suspensions 
 
5.3.2.1.1 Blood 
For blood isolation, animals were sacrificed using CO2; mouse blood was obtained by puncture of 
the orbital vein of mice. For FACS staining, 30 µl of heparin were added to 1 ml of blood. For 
the detection of IFN-γ in the serum or adoptive transfer memory experiments, blood was 
coagulated in 1.5 ml tubes for 1 h at 4°C. The serum was separated by centrifugation (1500 rpm, 
10 min, 4°C). 
 
5.3.2.1.2 Spleen and LN 
Animals were sacrificed by dislocation of the neck; spleen and peripheral LN were excised using 
sterile forceps and scissors and kept in ice-cold PBS + 5% FCS medium. Single cell suspensions 
were obtained by mincing the spleen or LN through a 40 μm cell strainer. For the lysis of 
erythrocytes, splenocytes were treated with buffered ammonium chloride potassium phosphate 
solution (ACK-buffer) for 1 min at RT and then washed with PBS + 5% FCS (1400 rpm, 10 min, 
4°C). Cells were resuspended in PBS + 5% FCS. 
 
5.3.2.1.3 Tumor infiltrating leukocytes 
For the preparation of single cell suspensions from tumors, tumors were excised using sterile 
forceps, cut into small pieces with a scalpel and digested with 5 mg/ml collagenase type IV and 
0.5 mg/ml DNase I for 15 min at 37oC. At the end of the incubation, the digested tumor was 
smashed through a 70 µm-pore cell strainer, cells were collected in a 50 ml Falcon tube and 
washed once with PBS + 10% FCS (1400 rpm, 10 min, 4°C). 
5.3.2.1.4 Bone marrow (BM) cells 
Animals were sacrificed by dislocation of the neck; hind legs were dissected and bones were 
freed from all sinews and muscle tissue using sterile forceps and scissors. The femur and tibiae 
were separated by breaking the knee and the heel, washed briefly in 80 % ethanol and placed in 
ice-cold PBS. To rinse out the BM cells, the ends of femur and tibiae were cut and 5-10 ml of 
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ice-cold PBS were forced through the bone cavity with a 27G needle. The isolated BM cells were 
washed three times with PBS before i.v. injection into the mice. 
 
5.3.2.2 In vivo depletion and neutralization experiments 
For the in vivo depletion of Treg, 300 µg of anti-CD25 mAb were injected i.p. 2 days before 
tumor cell inoculation. The depletion efficiency was >95% in blood after 2 days. In some 
experiments, mice were additionally depleted of NK1.1+ cells or CD4+ T cells by i.p. injection of 
200 µg anti-NK1.1 or anti-CD4 mAbs, respectively, on days -2, +2, +9, and +16. At day 10 after 
tumor cell inoculation and at the endpoint, the efficiency of these depletions was >90% in blood, 
spleen and tumor tissue, as assessed by flow cytometric analysis. For the in vivo neutralization of 
IFN-γ, 300 µg of anti-mouse IFN-γ mAb were injected i.p. three times weekly beginning at the 
day of tumor cell inoculation. For the in vivo neutralization of CD95L, 250 µg of anti-mouse 
CD95L mAb were injected i.p. every 3 days beginning from day -1 before tumor inoculation. The 
anti-apoptotic activity of the anti-CD95L mAb was confirmed in vitro by the inhibition of T cell 
activation-induced cell death, which is known to be mediated via the CD95-CD95L pathway 
(data not shown). For the in vivo neutralization of TGF-β, 2 mg of anti-TGF-β mAb were 
administered i.p. 2 times weekly, starting from day -2 before tumor inoculation. For the in vivo 
blocking of IL-10R, 1 mg of anti-IL-10R mAb was injected i.p. once weekly beginning from day 
-2 before tumor inoculation. 
 
5.3.2.3 Bone marrow transplantation 
Wt, IFNAR1-/- or RAG2-/-IFNAR1-/- mice were irradiated with two doses of 450 rad with a 3h 
interval in between. After 4 hours of rest, irradiated mice were injected with 4 x 106 bone marrow 
cells in 200 µl PBS collected from donor wt or IFNAR1-/- mice. Mice were maintained on 
amoxycilin antibiotic diluted in drinking water for 6 weeks after reconstitution. At 6 weeks after 
injection, chimeras were analyzed for the reconstitution of immune cell populations by flow 
cytometry of peripheral blood cells after staining with antibodies to CD45.1 and CD45.2. 
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5.3.2.4 Memory experiments 
5.3.2.4.1 In vivo memory experiments 
Mice which rejected RMA-S tumors after anti-CD25 treatment were rested for at least 3 months 
after primary tumor cell inoculation. The reconstitution of the Treg compartment at this time was 
confirmed in the blood of mice by flow cytometric analysis for CD4 and CD25 markers. For 
rechallenge experiments, mice were injected s.c. in the left flank with 1 x 106 RMA-S or RMA 
cells and tumor growth was monitored. In some experiments, mice were depleted of CD4+ or 
CD8+ T cells or NK1.1+ cells in combination either with CD4+ or CD8+ T cell depletion. Naïve 
mice injected for the first time with tumor cells were used as a control. 
 
5.3.2.4.2 Adoptive transfer memory experiments 
In adoptive transfer experiments, CD4+ and CD8+ T cells were isolated by magnetic separation 
from the spleens and LN of naïve mice or mice which had previously rejected RMA-S tumors 
and washed 3 times with PBS. The blood serum was also prepared from the same mice. 1 x 107 
purified CD4+ T cells or 6 x 107 CD8+ T cells or 250 µl of blood serum were injected i.v. to naïve 
C57BL/6 hosts, one day before s.c. RMA-S tumor cell inoculation. 
 
5.3.3 Antibody purification 
5.3.3.1 Purification of the anti-CD25 mAb 
For the purification of the anti-CD25 mAb, PC61 hybridoma cell line was expanded until 
confluence. Cell cultures were centrifuged (3500 rpm, 7 min, 4oC) and S/N was collected. Total 
protein was precipitated with ammonium sulfate added at slow rate to the S/N until saturation. 
The S/N was shaken on a magnetic stirrer for ~1h at RT. After centrifugation (7500 rpm, 30 min, 
4oC), pellets were resuspended in 100 ml ddH2O and dialyzed O/N at 4oC in 1x PBS. The 
dialyzed mAb was sterile filtered and purified by binding on a protein G column with the means 
of a peristaltic pump, pre-washed once with ethanol, and once with the binding buffer. The mAb 
solution was passed through the column twice at a flow rate 4 ml/min. The bound mAb was 
eluted from the column with 30-50 ml elution buffer and fractions were collected in 15 ml falcon 
tubes containing 200 µl neutralization buffer. Additional neutralization buffer was added to 
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adjust the pH to 7. Optical density (O.D.) was measured at 260 nm; the fractions which had an 
O.D. over 0.6 were pooled. The pooled mAb was dialyzed O/N in 1x PBS and sterile filtered. 
Protein concentration was analyzed with the BCA kit and purity with a SDS-gel. Aliquots of the 
mAb were kept at -20oC. The protein G column was washed with ethanol and stored at 4oC. 
 
5.3.3.2 Purification of the anti- IFN-β mAb 
For the purification of the anti-IFN-β mAb, the 7FD3 hybridoma cell line was expanded until 
confluence. FCS was excluded from the cell culture medium during the last step of culture. Cell 
cultures were centrifuged (3500 rpm, 7 min, 4oC) and S/N was collected. Total protein was 
precipitated with ammonium sulfate added at slow rate to the S/N until 50% saturation. The S/N 
was shaken on a magnetic stirrer for ~1h at RT. After centrifugation (7500rpm, 30min, 4oC), 
pellets were resuspended in ddH2O in a volume corresponding to 0,5% of the starting volume  
and dialyzed O/N at 4oC in 1x PBS. The dialyzed mAb was sterile filtered. Protein concentration 
was analyzed with the BCA kit and purity with a SDS-gel. Aliquots of the mAb were kept at 4oC.  
 
5.3.4 Fluorescence-activated cell sorting (FACS) 
5.3.4.1 FACS staining and analysis 
For staining of cells, 0.5 – 1 x 106 cells were washed once with FACS buffer (1200 rpm, 10 min, 
4°C for cell lines or 1400 rpm, 10 min, 4°C for primary mouse cells) and incubated with 10% Fc 
block (2.4G2 supernatant) for 10 min on ice to block Fc receptors. Subsequently, the primary 
antibodies were added and cells were further incubated for 30 min at 4°C. For biotinylated 
antibodies, cells were washed once with FACS buffer and stained with conjugated streptavidin 
for additional 30 min at 4°C. After staining, cells were washed once, fluorescence was assessed 
by a FACSCalibur and data were analyzed with the CellQuest software. Peripheral blood 
leucocytes were stained by adding the primary antibodies directly into the blood samples. At the 
end of the incubation, erythrocytes were lysed with FACS Lysis Buffer for 1 min at RT, followed 
by washing with FACS buffer. Streptavidin was added at a second step when necessary. Working 
concentrations of antibodies are denoted under chapter 5.1.6.1. 
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5.3.4.2 FACS sorting 
For FACS sorting, up to 1 x 108 total tumor cells were washed once with PBS + 0.1% FCS (1400 
rpm, 10 min, 4°C,) and incubated with 10% Fc block (2.4G2 supernatant) for 10min on ice to 
block Fc receptors. Subsequently, the primary antibodies were added and cells were further 
incubated for 30 min at 4°C. After staining, cells were washed once with PBS + 0.1% FCS, 
resuspended in PBS + 1% FCS and filtered through a cell strainer to remove cell clusters. Cell 
sorting was performed with FACSDiva and FACSVantage. 
 
5.3.5 MACS sorting 
In some cases, primary cell subpopulations were sorted with magnetic beads, according to the 
manufacturer’s protocol. 
 
5.3.6 Determination of cytokines 
5.3.6.1 Intracellular FACS staining 
For the detection of IFN-γ producing cells, single cell suspensions were prepared from tumor 
tissue of PBS and anti-CD25 treated mice. Cells were stained for extracellular markers and 
subsequently fixed with 50 µl of 4% PFA for 10 min at RT. Cells were washed once (1400 rpm, 
10 min, 4°C,) with cold FACS buffer and permeabilized with 100 µl of 0.5% saponin for 10 min 
at RT. 10% Fc block and 10 µg/ml rat IgG were added for additional 10 min to block unspecific 
binding. Cells were subsequently washed once (1400 rpm, 10 min, 4°C) with cold FACS buffer 
containing 0.5% saponin. Anti-IFN-γ or the appropriate isotype control was added and cells were 
incubated for 30 min at 4oC. Cells were washed once (1400 rpm, 10 min, 4°C) with cold FACS 
buffer containing 0.5% saponin and once (1400 rpm, 10 min, 4°C) with cold FACS buffer, before 
analyzed with the CellQuest software on a FACSCalibur. 
 
5.3.6.2 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
CD8+ T cells were purified from spleens and LN by magnetic cell sorting or from tumor tissue of 
tumor bearing mice by FACS sorting. 1 x 105 CD8+ T cells were cultured either alone or in the 
presence of RMA-S or EC7.1 cells at a ratio 1:1 for 18h. At the end of the incubation, S/N were 
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collected and stored at -20oC until used. IFN-γ levels were determined by ELISA for murine 
IFN-γ, according to the manufacturer’s instructions.  
 
5.3.6.3 In vivo IFN-γ capture assay 
For the determination of IFN-γ in the serum of naïve or tumor bearing mice treated with PBS or 
anti-CD25 mAb, biotinylated anti-IFN-γ mAb was injected i.v. into the mice on days 0, 3, 5 and 9 
after RMA-S tumor cell inoculation and blood samples were collected after 24 or 48 h. Blood 
serum was prepared and the levels of IFN-γ were determined according to the manufacturer’s 
instructions. 
 
5.3.6.4 Bio-plex protein array assay for cytokine measurement 
For the determination of cytokine and chemokine production by tumor infiltrating macrophages, 
CD11b+F4/80+ cells were isolated from tumors of control and Treg depleted mice on day 10 after 
RMA-S tumor cell inoculation by flow cytometric sorting (purity > 95%). 1 x 105 macrophages 
were cultured in 200µl primary cell culture medium in a U-bottom 96-well plate and after 12 or 
24h supernatants were collected. For the determination of cytokine and chemokine production in 
tumor tissue, lysates were prepared from total tumor tissue in the presence of PMSF as protease 
inhibitor. Total protein concentration was calculated with the BCA kit and the concentration of 
all lysate samples was adjusted optimally to 300 µg/ml with the Bio-plex lysis buffer. All 
supernatants and lysates were further diluted 1:1 with mouse serum before the assay. Cytokine 
and chemokine release was determined with the Bio-plex Protein Array system, according to the 
manufacturer’s instructions. The sensitivity of the assay for IFN-γ detection was 2 pg/ml, for 
MIP-1β 1.5 pg/ml, for MIP-2 3 pg/ml, for IL-6 1 pg/ml, for IL-13 3 pg/ml and for IL-1b 1.6 
pg/ml. 
 
5.3.7 Proliferation and suppression assays 
5.3.7.1 Treg suppression assay 
CD4+ T cells were isolated from mouse splenocytes based on a negative magnetic selection 
procedure; Treg (CD4+CD25+ T cells) and Tcon (CD4+CD25- T cells) were subsequently selected 
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from the pure, untouched CD4+ T cells, based on CD25 magnetic separation. Both populations 
had a purity of ~90%. To document the suppressive activity of Treg, 1 x 105 Tcon were incubated 
in U bottom 96-well plates in 200 µl of primary cell culture medium alone or in co-culture with 
titrating cell numbers of Treg in the following Treg : Tcon ratios: 1:1, 1:2, 1:4, 1:8, 1:16. For the 
stimulation of proliferation of T cells, 0.5 µg/ml mouse anti-CD3 mAb was added to the culture 
medium and 1 × 105 irradiated (30 Gray) CD90-depleted splenocytes served as APC. After 
4 days of culture at 37°C in 5% CO2, 1 µCi 3H-thymidine, diluted 1:10 in RPMI medium, per 
well was added for additional 16 h. To control non-specific inhibition due to crowding in the 
well, 2x Tcon were used as a control. Proliferation was measured using a scintillation counter. 
 
5.3.7.2 Tumor cell growth inhibition assay 
CD11b+ cells were isolated with magnetic separation (purity ~50%) or macrophages were 
purified with FACS sorting (purity > 95% CD11b+F4/80+) from tumors on d10 after tumor cell 
inoculation. The purified cell populations were cultured in 96-well plates with 1 x 104 RMA-S 
cells at the following ratios: CD11b+ cells : RMA-S cells = 5:1, 10:1, 20:1 and 40:1 – depending 
on the assay – for 24 or 48 h in a U-bottom 96-well plate in 200 µl of primary cell culture 
medium. RMA-S cells were in parallel cultured in the absence of CD11b+ cells. In some 
experiments, CD11b+ cells were separated from RMA-S cells by transwell inserts. In some 
experiments, inhibitors were used to block the activity of iNOS, PGE2 and IDO: 0.5 mM L-
NMMA and its stereoisomer D-NMMA as a control, 10µM indomethacin and EtOH diluent 
control, and 100µM 1MT and HCl diluent control, respectively. Proliferation was assessed by 
adding 1µCi of 3H-thymidine, diluted 1:10 in RPMI medium, to each well, 6h before harvesting. 
At the end of the incubation, the cells were harvested on filter papers, signal was enhanced by the 
addition of a scintillator and the radioactivity was quantified by a beta counter. In cases where the 
plates could not be harvested immediately after the end of the incubation, the plates were placed 
in -20oC until analyzed for 3H-thymidine incorporation. Before harvesting, plates were thawed at 
37oC. 
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5.3.7.3 Documentation of proliferation by CFSE dilution 
A total of 1 x 107 RMA-S cells diluted in 1 ml PBS + 5% FCS were labeled with 1 µM CFSE, 
which was added to the cells while vortexing. After 10 min incubation at RT on shaker, the cells 
were washed with PBS + 5% FCS three times (1200 rpm, 10 min, 4°C). During the procedure, 
the cells were protected from the light. 1 x 104 CFSE-labeled RMA-S cells were cultured alone or 
in the presence of CD11b+ cells at a ratio of CD11b+ cells : RMA-S cells = 40 :1 for 48 h in a U-
bottom 96-well plate in 200 µl of primary cell culture medium. At the end of the incubation, cells 
were harvested from the plate, washed once with FACS buffer (1400 rpm, 10 min, 4°C) and 
fluorescence was analyzed on a FACSCalibur. Dilution of the CFSE dye corresponded to 
proliferation of the cells. 
 
5.3.8 Killing assays 
5.3.8.1 51Cr release cytotoxicity assay 
RMA-S or YAC-1 tumor cells were labeled with 100µCi 51Cr for 90min and washed three times 
with RPMI medium. A total of 1 x 103 51Cr-labeled target cells were seeded in each well of a 96-
well U-bottom plate. NK cells, purified with DX5+ magnetic cell sorting, were added at different 
effector to target (E:T) ratios (100:1, 50:1, 25:1, 12.5:1, 6.25:1, 3.125:1, 1.56:1) in a final volume 
of 200 µl of primary cell culture medium. The plates were centrifuged at 1200 rpm for 3 min and 
incubated for 6 h at 37oC in 5% CO2. At the end of the incubation, 100 µl of S/N was collected 
from each well and the radioactivity was counted in a beta counter. The percentage of 
cytotoxicity in each well was calculated as:  
[mean cpm – minimum (spontaneous) mean release]  x 100 
[maximum release (total) – minimum (spontaneous) mean release]  
Minimum (spontaneous release) corresponds to the amount of radioactivity released by tumor 
cells cultured in the absence of NK cells. Maximum release relates to the amount of radioactivity 
released by tumor cells cultured in the presence of 10% Triton X-100. 
 
5.3.8.2 In vitro induction of apoptosis by death ligands 
RMA-S cells were cultured at a concentration of 1 x 105 cells/ml in the absence or presence of 50 
U/ml recombinant mouse IFN-γ for 24h. At the end of the incubation, cells were washed (1200 
Ioanna E. Galani                                                        Materials and Methods 
 50
rpm, 10 min, 4°C) twice and re-plated at a concentration of 1 x 106 cells/ml in a 6-well plate for 
6h in the absence or presence of either 0.1 µM TNF-α or 1 µg/ml TRAIL. In parallel, L929 cells 
were cultured in the absence or presence of TNF-α, and Jurkat cells in the absence or presence of 
TRAIL, as positive controls to TNF-α- and TRAIL-induced apoptosis in vitro. At the end of the 
incubation, cells were harvested, washed once (1200 rpm, 10 min, 4°C) with FACS buffer and 
stained with 1µl of PI. Dead cells, defined as PI+ cells, were determined by flow cytometric 
analysis as percentage of total cells. 
 
5.3.9 Visualization of angiogenesis by confocal microscopy 
Tumor vasculature was visualized by fluorescent angiography using a FITC-labeled Lycopersicon 
esculentum lectin injected i.v. (100 µg diluted in 100 µl of PBS) in the tail vein of mice. Two min 
after lectin injection, mice were sacrificed by cervical dislocation. Tumors were harvested, placed 
on 0.17 mm thick coverslips and examined unfixed under fluorescent confocal microscopy 
(Nikon C1Si confocal microscope with a 488-nm argon ion laser). Detection of the Lycopersicon 
esculentum lectin was achieved at 503–537 nm. Datasets typically represented 1 x 1 x 0.1 mm 
(512 x 512 pixels x 61 planes) with a 1.65 µm step interval. The analysis used the entire z-series 
of all three channels. 
 
5.3.10 Statistical analysis 
Differences between groups were calculated using standard Student’s t test. Differences in tumor 
growth between groups of mice were calculated using Koziol test. Values of p < 0.05 were 
considered to be statistically significant. 




6.1 REGULATORY T CELLS SUPPRESS ANTI-TUMOR IMMUNITY 
AGAINST A MHC CLASS I DEFICIENT LYMPHOMA 
 
6.1.1 Regulatory T cells suppress IFN-γ dependent leukocyte accumulation in 
lymphoma 
 
6.1.1.1 Accumulation of Treg in RMA-S tumor-bearing mice 
RMA-S lymphoma cell line is a MHC class I-deficient variant of the RBL-5 tumor. According to 
the original characterization by Kärre and colleagues, RMA-S tumor cells are efficiently 
controlled by NK cells, when injected into mice at relatively low cell numbers 271. For our study, 
we used a higher tumor cell number (1 x 106 cells) leading to progressive tumor growth after s.c. 
injection. In order to investigate the role of Treg in the anti-tumor immunity against a MHC class 
I-deficient tumor, we examined spleens and tumor tissues from RMA-S tumor-bearing mice for 
the presence of Treg. Flow cytometric analysis revealed that the percentages of CD4+CD25+ T 
cells among CD4+ T cells were significantly increased in spleens of tumor-bearing mice (Figure 
6.1A). High percentages of CD4+CD25+ T cells among CD4+ T cells were also observed within 
the tumor infiltrating leukocytes. Since CD25 expression is also upregulated on CD4+CD25− 
effector T cells after activation, we determined the percentages of CD4+ T cells expressing the 
Treg specific transcription factor Foxp3. Our results confirmed the significantly increased 
percentages of Treg in spleens of tumor-bearing mice and high percentages of Treg in the tumor 
tissue (Figure 6.1B). Interestingly, CD25 expression was not observed in any cell population 
other than Treg. CD25 expression correlated with suppressive ability, since CD4+CD25+ T cells 
were able to suppress the proliferation of CD4+CD25− T cells in an in vitro co-culture in a dose-
dependent manner (Figure 6.1C). Our results demonstrate that in the RMA-S tumor model Treg 
accumulate in the spleen and are present in high percentages within the tumor tissue. 
 


















Figure 6.1. Increased numbers of Treg in mice bearing RMA-S tumors. (A-B) C57BL/6 mice were injected s.c. 
with RMA-S cells. After 21 days spleens and tumors were removed and analyzed for the presence of CD4+CD25+ 
(A) or CD4+Foxp3+ (B) T cells by flow cytometry. Representative dot plots show CD4 and CD25 staining (A) or 
CD4 and Foxp3 staining (B) of total splenocytes (left panels). Right panels depict quantification of CD4+CD25+ (A) 
or CD4+Foxp3+ (B) T cells in spleens of control and tumor-bearing mice as well as in tumor tissue. The percentages 
of CD25+ cells (A, gate R2) or Foxp3+ cells (B, gate R2) among total CD4+ T cells (gate R1) were calculated. Data 
show the mean ± SD of eight animals per group and are representative of three experiments. *, p<0.01 using 
Student’s t test. (C) Tcon (CD4+CD25– T cells) from C57BL/6 naïve mice were stimulated with anti-CD3 mAb and 
irradiated syngeneic T cell-depleted splenocytes in the presence of varying numbers of Treg (CD4+CD25+ T cells). 
Cells were cultured for 96 h and proliferation was assessed by 3H-thymidine-incorporation, added for additional 16 h 
to the culture. To control for nonspecific inhibition due to crowding in the well, 2x Tcon were used as a control. Data 
show the mean ± SD of triplicate cultures and are representative of three experiments. *, p<0.05, **, p<0.01, ***, 
p<0.005, using Student’s t test.  
 
6.1.1.2 Depletion of Treg abrogates RMA-S tumor growth  
To examine the impact of Treg on the immune response against RMA-S tumor, Treg were 
depleted by i.p. injection of anti-CD25 mAb 2 days prior to RMA-S tumor cell inoculation. Of 
note, CD25 expression was not detectable on RMA-S cells cultured in vitro or isolated ex vivo 
C
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from tumor-bearing mice (Figure 6.2). When mice were depleted of Treg, tumor growth initially 
progressed similar to the control group (Figure 6.3A). However, 10 days after tumor cell 
injection, tumors started to decrease in size and were eventually rejected in the majority of Treg 
depleted mice, whereas tumors continued to progressively grow in the PBS-treated control group. 
Similar results were obtained upon s.c. inoculation of RMA cells transduced with RAE-1, a 
ligand for the NK cell activating receptor NKG2D 69,70 (Figure 6.3B). These results demonstrate 
that Treg suppress the rejection of NK cell sensitive tumors, like the MHC class I-deficient 







Figure 6.2. RMA-S cells do not express CD25. (A-C) Representative histogram plots documenting CD25 
expression, as assessed by flow cytometry, on RMA-S cells cultured in vitro (A), RMA-S cells isolated from the 
tumors of RMA-S tumor bearing mice 21 days after s.c. tumor cell inoculation (B) and total splenic CD4+ T cells 
(C). Staining with the specific antibody is indicated by the black line and the corresponding isotype control by the 
grey filled area. The data are representative of two experiments. 
 
6.1.1.3 NK1.1+ cells and CD4+CD25- T cells mediate the rejection of RMA-S tumors in the 
absence of Treg 
In order to investigate whether NK1.1+ cells were required for the rejection of RMA-S tumors in 
the absence of Treg, we depleted NK1.1+ cells alone or in combination with Treg depletion. 
Depletion of NK1.1+ cells alone led to accelerated tumor growth in comparison to the PBS-
treated control group, emphasizing the importance of this cell population for the control of 
RMA-S tumor growth (Figure 6.3C, left panel). In the absence of Treg, NK1.1+ cell depletion 
initially resulted in an accelerated tumor growth, followed by a decrease in tumor size after day 
10 of tumor inoculation (Figure 6.3C, right panel). This remarkable regression in the absence of 
NK1.1+ cells, however, did not lead to complete tumor eradication, possibly due to the higher 
initial tumor load caused by the absence of NK1.1+ cells. In summary, NK1.1 depletion led to 
enhanced tumor growth at early time points as depicted for day 7, irrespective of the presence or 
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RMA-RAE-1γRMA-S
Figure 6.3. NK1.1+ cells and CD4+CD25- T cells mediate rejection of RMA-S tumors in the absence of Treg. 
(A) C57BL/6 mice were treated with PBS (left panel, n=8) or anti-CD25 mAb (right panel, n=6), before s.c. 
inoculation with RMA-S cells and tumor growth was monitored. (B) C57BL/6 mice were treated with PBS (left 
panel, n=10) or anti-CD25 mAb (right panel, n=10), before s.c. inoculation with RMA-RAE-1g cells and tumor 
growth was monitored. (C) C57BL/6 mice were treated with anti-NK1.1 (left panel, n=8) or anti-CD25 and anti-
NK1.1 mAb (right panel, n=7), inoculated s.c. with RMA-S cells and tumor growth was monitored. (D) Bar graphs 
showing two representative time points of tumor growth as described in panels A and C. (E) Groups of 9 C57BL/6 
mice were treated with PBS or anti-CD4 mAb, inoculated s.c. with RMA-S cells and tumor growth was monitored. 
Two representative time points of tumor growth are depicted in bar graphs. (F) C57BL/6 RAG2-/- mice were injected 
i.v. with PBS (left panel, n=7) or 2x106 CD4+ T cells (middle panel, n=7) or 2x106 CD4+CD25- T cells (right panel, 
n=5), 8 days before s.c. inoculation with RMA-S cells, and tumor growth was monitored. (D-E) Error bars depict SD 
of individual mice in the experiment. (A-C and F) Each line represents one single mouse. The results are 
representative of four (A), three (C) and two (B, E and F) experiments. *, p<0.005, **, p<0.0005 using Student’s t 
test. 
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absence of Treg (Figure 6.3D, left panel), whereas Treg depletion had a strong impact on day 19 
representing a later time point of tumor growth (Figure 6.3D, right panel). These data suggest that 
the initial phase of RMA-S tumor growth is controlled by NK1.1+ cells regardless of the presence 
of Treg. 
 In several tumor models, depletion of the whole CD4+ T cell compartment, comprising 
Treg, conventional CD4+ T cells and a subset of NKT cells, had a similar impact on tumor 
growth as compared to Treg depletion alone 272,273. Interestingly, in our model, depletion of the 
whole CD4+ T cell compartment led to progressive tumor growth, which was even enhanced 
compared to the control group at a later time point, as depicted for day 14 (Figure 6.3E). 
Therefore, in the absence of Treg, conventional CD4+CD25− T cells are important for the 
rejection of RMA-S tumors. The importance of CD4+CD25− T cells in the anti-tumor response 
against RMA-S cells was analyzed in RAG2-/- mice. Total CD4+ T cells including Treg, or 
CD4+CD25− conventional T cells, isolated from naïve wt mice, were adoptively transferred into 
RAG2-/- recipients before s.c. inoculation of RMA-S tumor cells. Tumor growth in these mice 
was compared with tumor growth in RAG2-/- mice which did not receive any cells (PBS group). 
Adoptive transfer of the whole CD4+ T cell compartment hardly affected RMA-S tumor growth 
when compared to mice which did not receive any cells (Figure 6.3F, left and middle panel). 
Most importantly, mice which received CD4+CD25− T cells exhibited reduced tumor growth 
compared to mice which received the whole CD4+ T cell compartment (Figure 6.3F, middle and 
right panel). This observation implies that Treg suppress CD4+CD25− T cells during the anti-
tumor response against RMA-S cells. 
In conclusion, in the absence of Treg, NK1.1+ cells and CD4+ T cells are required for 
efficient rejection of high numbers of RMA-S tumor cells.  
 
6.1.1.4 Depletion of Treg leads to the generation of anti-tumor memory responses against 
RMA-S tumor cells 
In a further step, we determined whether RMA-S tumor rejection in the absence of Treg also 
leads to the generation of immunological memory. Mice, which had rejected RMA-S tumors in 
the absence of Treg, were rechallenged with RMA-S tumor cells after being rested for 3 months. 
Mice, inoculated with tumor cells for the first time, were used as controls. In mice depleted of 
CD25+ T cells during the primary response, the Treg compartment had completely recovered on 
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Figure 6.4. Protective memory is generated in the absence of Treg. (A-F) C57BL/6 mice were treated with anti-
CD25 mAb before s.c. inoculation with RMA-S cells, rejected RMA-S tumors and rested for at least 3 months. 
These mice are designated as memory mice. (A) Three months after RMA-S tumor cell inoculation, the presence of 
CD4+CD25+ T cells was assessed by flow cytometry in the blood of memory (upper panels) versus naïve (lower 
panels) mice. Representative dot plots show CD4 and CD25 staining of PBL (left panels) or gated CD4+ T cells 
(right panels). The percentages of CD25+ cells (gate R3) among total CD4+ T cells (gate R2) were calculated. (B) 
Naïve C57BL/6 mice (n=24, closed circles) or memory mice (n=17, open circles) were inoculated s.c. with RMA-S 
cells and tumor growth was monitored. (C) Naïve C57BL/6 mice (n=6) or memory mice (n=4) were inoculated s.c. 
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with RMA cells and tumor growth was monitored. (D) Memory mice were treated with PBS (n=4), anti-CD4 (n=4) 
or anti-CD8 (n=4) mAb, as designated, and inoculated s.c. with 1 x 106 RMA-S cells. Naïve C57BL/6 mice (n=5) 
were also inoculated with RMA-S cells and tumor growth was monitored. (E) Memory mice were treated with PBS 
(n=5) or a combination of anti-CD4/NK1.1 (n=5) or anti-CD8/NK1.1 (n=5) mAb, as designated, and inoculated s.c. 
with RMA-S cells. Naïve C57BL/6 mice (n=5) were also inoculated with RMA-S cells and tumor growth was 
monitored. (F) CD4+ or CD8+ T cells or blood serum were isolated from memory or naïve mice, as designated, and 
transferred into naïve recipients before s.c. inoculation with RMA-S cells. Mice which did not receive any cells or 
serum were used as a control. A representative time point (day 18) of tumor growth is depicted in bar graphs. *, 
p<0.01 using Student’s t test. The results are representative of four (B), two (A, D and F) and one (C and E) 
experiments. 
 
the time of rechallenge, as determined by flow cytometric analysis 3 months after the primary 
challenge (Figure 6.4A). Thus, Treg were present at normal cell numbers at rechallenge. Upon 
rechallenge, protective immunity against the RMA-S tumor cells was observed in 100% of mice, 
whereas progressive tumor growth occurred in almost all of the mice that were injected with 
RMA-S cells for the first time (Figure 6.4B). Mice that had rejected RMA-S tumors after Treg 
depletion were also protected against the MHC class I-positive RMA tumor cells (Figure 6.4C). 
In order to assess the nature of the memory induced in the absence of Treg, mice were 
depleted of various cell compartments before rechallenge with RMA-S cells. CD4+ or CD8+ T 
cell depletion alone was not sufficient to abrogate the memory response observed upon a 
secondary challenge with RMA-S cells (Figure 6.4D). Interestingly, simultaneous depletion of 
NK1.1+ and CD4+ cells or NK1.1+ and CD8+ cells only partially abrogated the memory response 
to a secondary challenge of RMA-S cells (Figure 6.4E). To gain further insight into the cell 
population(s) which mediate(s) memory responses against RMA-S tumor cells, CD4+ T cells, 
CD8+ T cells and blood serum were isolated from mice that had previously rejected RMA-S 
tumors after Treg depletion and were rested for at least 3 months after tumor cell inoculation; 
these mice are designated as memory mice from hereon. The cells or serum were subsequently 
transferred into naïve hosts prior to challenge with RMA-S cells. As shown in Figure 6.4F, 
transfer of CD4+ T cells and, more prominently, of CD8+ T cells isolated from memory mice had 
a protective effect for the hosts, since it led to reduced tumor growth in comparison to the mice 
which did not receive any cells or which received CD4+ T cells or CD8+ T cells isolated from 
naive mice. The role of CD8+ T cells in RMA-S anti-tumor immunity is discussed in paragraph 
[4.1.3]. Transfer of serum isolated either from memory or naïve mice did not have any influence 
in tumor growth, excluding a role for humoral immunity in the RMA-S model. In summary our 
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results demonstrate that immune responses induced during Treg depletion led to the generation of 
protective cell-mediated immunological memory. 
 
6.1.1.5 Neutralization of IFN-γ abrogates RMA-S tumor rejection mediated by Treg 
depletion in vivo 
IFN-γ was shown to mediate anti-tumor immune responses by several mechanisms 2,274. 
Therefore, we sought of determining the levels of IFN-γ in the RMA-S model in the presence and 
absence of Treg. First, we assessed whether depletion of Treg would induce systemically 
increased levels of IFN-γ. Measurement of in vivo cytokine production is problematic owing to 
the rapid utilization, catabolization, and excretion of the cytokines quickly after secretion. We, 
therefore, used an in vivo IFN-γ capture assay, an adaptation of the standard cytokine ELISA 275. 
This assay facilitates the measurement of cytokines in serum by increasing their in vivo half lives 
up to 1000-fold after in vivo administration of a biotinylated neutralizing mAb. Thus, we 
determined the levels of IFN-γ in the blood serum prepared from control or Treg depleted mice, 
3, 5 and 9 days after RMA-S tumor inoculation and compared them with those found in the blood 
serum of naïve mice. No statistically significant difference in the levels of IFN-γ between control 
and Treg depleted mice or between naïve and tumor bearing mice was found (Figure 6.5A). 
These data suggest that during the anti-tumor response against RMA-S cells, no systemic IFN-γ 
production occurs. 
In a second step, we determined IFN-γ levels, locally, in the tumor tissue. Significantly 
increased levels of this cytokine were detected in RMA-S tumors of Treg depleted mice relative 
to the PBS group (Figure 6.5B). By intracellular staining, we observed that IFN-γ was 
predominantly produced by CD8+ T cells, NK cells and to a lower extent by CD4+ T cells in the 
tumor tissue (Figure 6.5C). Most importantly, the percentages of IFN-γ-producing cells were 
increased in the absence of Treg, suggesting a suppressive effect by Treg. Thus, we studied the 
contribution of IFN-γ to RMA-S tumor rejection in the absence of Treg. Figure 6.5D shows that, 
although CD25+ cell depletion alone led to tumor rejection, combined treatment of mice with 
anti-CD25 and neutralizing anti-IFN-γ mAb abrogated this effect resulting in tumor growth with 
similar kinetics as in the control mice. The presence of IFN-γ was important during the first week 
after tumor inoculation, since neutralization of IFN-γ solely after day 7 of tumor inoculation only 
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minimally affected tumor growth in the absence of Treg (data not shown). These results 
demonstrate that Treg suppress IFN-γ production and that IFN-γ is crucial for the rejection of 

























Figure 6.5. IFN-γ is required for RMA-S tumor rejection in the absence of Treg. (A) C57BL/6 mice were 
treated with PBS or anti-CD25 mAb, as indicated, and were inoculated s.c. with RMA-S cells. Three, 5 and 9 days 
after tumor cell inoculation, mice were injected i.v. with anti-IFN-γ biotin-conjugated mAb and blood serum was 
collected 24 or 48h after injections. IFN-γ levels in the serum were subsequently determined with an in vivo capture 
assay. Naïve C57BL/6 mice which were not inoculated with RMA-S cells were used as a control. The data show the 
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indicated. 10 days later tumors were removed and IFN-γ levels were determined in total tumor lysates by Bioplex 
analysis. Data show the mean ± SD of lysates from seven animals per group. *, p<0.05 using Student’s t test. (C) 
C57BL/6 mice were treated with PBS (n=3) or anti-CD25 mAb (n=3), as indicated. 10 days later tumors were 
removed, pooled single cell suspensions were prepared, and IFN-γ positive CD4+ T cells, CD8+ T cells or NK cells 
(NK1.1+CD3-) were determined by intracellular staining. (D) C57BL/6 mice were treated with PBS (left panel, n=8) 
or anti-CD25 mAb (middle panel, n=8) or anti-CD25 and anti-IFN-γ mAb (right panel, n=5), inoculated s.c. with 
RMA-S cells and tumor growth was monitored. (E) Representative histogram plot documenting CD119 (IFN-gR, a 
chain) expression on RMA-S cells, as assessed by flow cytometry. Staining with the specific antibody is indicated by 
the black line and the corresponding isotype control by the grey filled area. (F) C57BL/6 IFN-γR-/- mice were treated 
with PBS (n=8) or anti-CD25 mAb (n=8), as indicated, before s.c. inoculation with RMA-S cells, and tumor growth 
was monitored. (D and F) Each line represents one single mouse. The results are representative of two (C, D and F) 
and one (A, B and E) experiments.  
 
 Next, we tested whether IFN-γ acted directly on RMA-S cells or on cells of the host to 
mediate tumor rejection in the absence of Treg. To address this question, we injected RMA-S 
cells, which express IFN-γR (Figure 6.5E), into IFN-γR-/- mice. In this experimental setup, only 
the tumor cells responded to IFN-γ. Subsequent monitoring of tumor growth revealed that 
IFN-γR-/- mice exhibited enhanced tumor growth in comparison to the wt controls, indicating the 
contribution of IFN-γ signaling on host cells for tumor control in the presence of Treg (Figure 
6.5F). More importantly, depletion of Treg had no impact on tumor growth in IFN-γR-/- mice in 
comparison to IFN-γR-/- mice injected with PBS (Figure 6.5F). This finding suggests that IFN-γ 
signaling in host cells is essential for tumor rejection in the absence of Treg. 
 
6.1.1.6 Perforin, FasL and inhibition of angiogenesis are not involved in the rejection of 
RMA-S tumor in the absence of Treg 
In order to determine the mechanism leading to RMA-S tumor rejection in the absence of Treg, 
we investigated the role of perforin and the CD95-CD95L pathway. Perforin-mediated 
cytotoxicity has been shown to be important for the control of RMA-S tumor growth by NK cells 
20. While perforin-/- mice showed enhanced RMA-S tumor growth in comparison to the wt group 
in the presence of Treg, reduced tumor growth was observed in these mice after Treg depletion 
(Figure 6.6A). The CD95-CD95L pathway is known to be important for CD4+ T cell-mediated 
cytotoxicity 276 and FACS staining revealed that RMA-S cells express CD95 (Figure 6.6B). 
Nevertheless, neutralization of CD95L in vivo by injection of MFL-4 mAb 277 did not 


































Figure 6.6. Perforin, CD95L and inhibition of angiogenesis are not involved in the rejection of RMA-S tumors 
in the absence of Treg. (A) Groups of 8 perforin-/- (Prf -/-) mice were treated with PBS or anti-CD25 mAb, as 
indicated, before s.c. inoculation with RMA-S cells, and tumor growth was monitored. The results are representative 
of two experiments. (B) Representative histogram plot documenting CD95 expression on RMA-S cells, as assessed 
by flow cytometry. Staining with the specific antibody is indicated by the black line and the corresponding isotype 
control by the grey filled area. (C) Groups of 5 C57BL/6 wt mice were treated with anti-CD25 and/or anti-CD95L 
mAb, as indicated, before s.c. inoculation with RMA-S cells and tumor growth was monitored. (A and C) Each line 
represents one single mouse. (D) RMA-S cells cultured in the absence or presence of 50U/ml IFN-γ for 24h were 
additionally cultured for 6h in the absence or presence of TNF-α or TRAIL and dead cells, defined as PI+ cells, were 
determined at the end of incubation by flow cytometric analysis. L929 and Jurkat cells were used as positive control 
for TNF-α- or TRAIL-induced in vitro apoptosis. (E) Groups of 3 C57BL/6 mice were treated with PBS, anti-CD25 
mAb, and/or anti-IFN-γ mAb, as indicated, before s.c. inoculation with RMA-S cells. Nine days later, mice were 
dissected and vessels leading to tumors were enumerated under a dissecting microscope. (F) Groups of 3 C57BL/6 
mice were treated with PBS or anti-CD25 mAb, as indicated, before s.c. inoculation with RMA-S cells. Ten days 
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later, FITC-labeled Lycopersicon esculentum lectin was injected i.v. into mice and the tumor vasculature was 
observed in unfixed tumors by confocal microscopy. 
 
influence neither tumor growth in the presence of Treg nor tumor rejection observed in the 
absence of Treg (Figure 6.6C). These data suggest that the anti-tumor effector mechanisms 
induced in the absence of Treg could still function in the absence of perforin and when CD95L 
was neutralized. In addition, cell viability of RMA-S cells, which were untreated or sensitized 
with IFN-γ, was not affected by incubation with TNF-α or TRAIL in vitro (Figure 6.6D). 
 Since IFN-γ was shown to inhibit tumor-induced angiogenesis 278, we determined vessel 
number and integrity in the presence or absence of Treg on day 10 of tumor growth, because at 
this time point the mean tumor sizes of control and Treg depleted mice were similar (Figure 
6.3A). To address this question, PBS treated and Treg depleted mice, which were in addition 
neutralized or not for IFN-γ, were dissected on day 9 after tumor cell injection and vessels 
leading to tumors were enumerated under a dissecting microscope. No difference in the number 
of vessels connected to the tumor was documented among mice of the different groups (Figure 
6.6E). For a more elaborate analysis of the tumor vasculature, FITC-labeled Lycopersicon 
esculentum lectin, an endothelial cell selective reagent, was injected into mice on day 10 of tumor 
growth and the tumor vasculature was observed by confocal microscopy. No differences 
regarding vessel number and vessel localization were observed between PBS and anti-CD25 
treated mice (Figure 6.6F). In addition, no extravasion of the FITC-lectin was detected in any of 
the mice of control or Treg depleted groups, indicating that the vessels infiltrating the tumor 
tissue were functional in both groups. These data render it unlikely that angiogenesis is affected 
in the absence of Treg. 
 
6.1.1.7 In the absence of Treg, increased numbers of leukocytes accumulate in the RMA-S 
tumor tissue in an IFN-γ dependent manner  
Tumor-infiltrating lymphocytes have been found in many tumors and their numbers have been 
correlated with control or progression of tumor growth. In a recent study, a high density of 
immune cells, including T cells, correlated with longer survival in patients with colorectal cancer 
279. Thus, we investigated the accumulation of leukocytes in the RMA-S tumors in the presence 
or absence of Treg. We determined the quantity of leukocytes as percentages of total live cells in 
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the tumor in mice treated with PBS or anti-CD25 mAb on days 7-10. To clearly distinguish 
between tumor cells and infiltrating leukocytes within the tumor tissue, we injected Ly5.2+ RMA-
S tumor cells into congenic C57BL/6-Ly5.1+ mice. Flow cytometric analysis revealed that 
infiltrating Ly5.1+ cells represented higher percentages of total cells in the tumors of Treg 
depleted mice (Figure 6.7A). There was a significant increase in both the percentages and 
absolute cell numbers of leukocytes accumulating within the tumor mass, when Treg were 
depleted (7.46 ± 2.46 x 105 cells in the PBS group versus 14.6 ± 4.3 x 105 cells in the anti-CD25 
group, p<0.0005). Absolute tumor cell numbers and tumor volume were virtually identical 
between the two groups at the investigated time points (data not shown).  
 Since we found a requirement of IFN-γ for tumor rejection in the absence of Treg (Figure 
6.5D), we asked whether the presence of IFN-γ is required for the accumulation of leukocytes. 
We neutralized IFN-γ in the presence or absence of Treg and determined percentages of Ly5.1+ 
leukocytes infiltrating the Ly5.2+ tumors. Interestingly, the enhanced leukocyte accumulation in 
the absence of Treg was abrogated when IFN-γ was neutralized. IFN-γ neutralization alone did 
not lead to a reduction in tumor-infiltrating leukocytes in comparison to the control group (Figure 
6.7A). In summary, these results indicate that Treg hamper leukocyte accumulation in the tumors, 
and this accumulation is IFN-γ dependent.  
 
6.1.1.8 Increased numbers of NK cells, conventional CD4+ T cells and macrophages are 
detected in the RMA-S tumors in the absence of Treg 
By analyzing individual leukocyte subpopulations, we observed that CD11b+ cells, NK cells 
(NK1.1+CD3-) and conventional CD4+ T cells (CD4+CD25-) were all increased in the absence of 
Treg (Figure 6.7B). The overall cellular composition of the infiltrating leukocyte compartment 
was comparable in both groups, with CD11b+ cells comprising up to 80% of all leukocytes. As 
observed with the whole Ly5.1+ compartment, the increased CD11b+ and CD4+ T cell 
accumulation in the absence of Treg was abrogated upon IFN-γ neutralization. Strikingly, almost 
no NK cells were detected in the tumor after IFN-γ neutralization (Figure 6.7B, insert). Figure 
6.7B demonstrates that CD11b+ cells were the most prominent leukocyte subpopulation 
infiltrating the RMA-S tumor tissue after depletion of Treg. We further characterized the various 
CD11b+ cell subtypes and determined their accumulation in the absence of Treg. Macrophages, 
defined as CD11b+F4/80+ cells, dendritic cells (DC), defined as CD11b+CD11c+ cells and 
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Figure 6.7. Increased numbers of leukocytes accumulate in the RMA-S tumors in an IFN-γ dependent manner 
in the absence of Treg. (A-C) C57BL/6-Ly5.1+ mice were treated with PBS (white bars) or anti-CD25 mAb (black 
bars) or anti-IFN-γ mAb (grey bars) or anti-CD25 and anti-IFN-γ mAb (checkered bars) and inoculated s.c. with 
Ly5.2+ RMA-S cells. Seven to 10 days later, tumors were removed and infiltrating Ly5.1+ (A), CD11b+, NK 
(NK1.1+CD3-) and CD4+CD25- cells (B), or CD11b+F4/80+ cells (C) were determined by flow cytometric analysis 
and quantified as percentages of total live cells in the tumor. (D) C57BL/6-Ly5.1+ mice were treated with PBS or 
anti-CD25 mAb or anti-CD4 mAb or anti-CD25 and anti-NK1.1 mAb and inoculated s.c. with Ly5.2+ RMA-S cells. 
Ten days later, tumors were removed and infiltrating CD11b+F4/80+ cells were determined by flow cytometric 
analysis and quantified as percentages of total live cells in the tumor. (A-B) Data are pooled from 4 independent 
experiments using 5 animals per group. (C-D) Data show the mean ± SD of 3-5 animals per group and are 
representative of three (C) and one (D) experiments. *, p<0.05, **, p<0.005 in comparison to the PBS group, using 
Student’s t test. n.a. = not analyzed. 
 
granulocytes, defined as CD11b+Gr-1+ cells, were all detected in significantly higher numbers 
within the tumor tissue on day 10 of tumor growth (Figure 6.7C). Similar to the whole CD11b+ 
compartment, the increased accumulation of all these populations in the absence of Treg was 
dependent on IFN-γ (Figure 6.7C). CD11b is also expressed on NK cells, characterizing their 
final maturation stage 17. Approximately 85% of the NK cells infiltrating the tumor tissue on day 
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10 of tumor growth were positive for the CD11b marker (Figure 6.18). However, the overall NK 
cell population is only a minor fraction of the whole CD11b+ population (Figure 6.7B). Cell 
depletion experiments revealed that predominantly CD4+ T cells and NK cells were important for 
the observed enhanced macrophage accumulation (Figure 6.7D). In summary, our data 
demonstrate that Treg suppress the accumulation of NK cells, CD4+CD25- T cells and CD11b+ 
cells, including macrophages, in the RMA-S tumors and this accumulation is IFN-γ dependent. In 
addition, NK cell accumulation in the tumors is absolutely dependent on IFN-γ, irrespective of 
the presence of Treg. 
 
Figure 6.8. Treg suppress the anti-tumor response against RMA-S independently of TGF-β or IL-10. (A) 
Groups of 8 C57BL/6 mice were treated with PBS (left panel) or anti-TGF-b mAb (middle panel) or the appropriate 
isotype control (mouse IgG1, right panel), were s.c. inoculated with RMA-S cells and tumor growth was monitored. 
Data are representative of two experiments. (B) Groups of 8 C57BL/6 mice were treated with PBS (left panel), anti-
IL-10R mAb (middle panel) or the appropriate isotype control (rat IgG1, right panel), were s.c. inoculated with 
RMA-S cells and tumor growth was monitored. (A and B) Each line represents one single mouse. 
6.1.1.9 Treg suppress RMA-S anti-tumor immunity independently of TGF-β or IL-10 
Finally, we wanted to address the question via which mechanism do Treg exert their suppressive 
effect on the anti-tumor immunity against RMA-S tumor. In certain in vivo models, Treg were 
shown to mediate their suppressive activity via the production of TGF-β 280. Thus, we examined 
whether neutralization of TGF-β in mice injected with RMA-S tumor cells would abrogate Treg 
mediated suppression and thus lead to a similar outcome on tumor growth as Treg depletion. 
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Figure 6.8A shows that after neutralization of TGF-β, RMA-S cells grew progressively similar to 
control mice. These data suggest that, in our model, Treg-mediated suppression is independent of 
TGF-β. Another important Treg-derived factor reported to mediate suppression is IL-10 281. In 
vivo administration of a blocking antibody against the IL-10R was not able to affect RMA-S 
tumor growth, when compared to the administration of an isotype-matched control (Figure 6.8B). 
In conclusion our data show that in the RMA-S tumor model Treg do not use neither TGF-β nor 
IL-10 to exert their suppressive function. 
 
 
6.1.2 Regulatory T cells suppress macrophage activation in lymphoma 
 
6.1.2.1 Increased amounts of MHC class II on macrophages in the absence of Treg 
The observation that CD11b+ cells were the most prominent cell population infiltrating the 
RMA-S tumors in the absence of Treg, along with the importance of CD4+ T cells for tumor 
rejection, prompted us to study MHC class II expression on tumor-infiltrating leukocytes on day 
10 of tumor growth. Interestingly, as shown in Figure 6.9A and 6.9B, left panel, higher 
percentages of MHC class II-expressing macrophages (CD11b+F4/80+) were found in the tumors 
of Treg depleted mice (49.6 ± 7.9% versus 28.4 ± 6.4% in the PBS group, p<0.05). Furthermore, 
the geometric mean fluorescence intensity (MFI) of MHC class II was also significantly 
increased on macrophages infiltrating the RMA-S tumors of the Treg depleted mice (Figure 6.9B, 
right panel). Notably, the MHC class II upregulation in the absence of Treg was abrogated by 
neutralization of IFN-γ, whereas IFN-γ neutralization alone did not have any significant effect on 
macrophage MHC class II expression (Figure 6.9B). Expression levels of the costimulatory          
molecules CD80 (B7-1) and CD86 (B7-2) on tumor-infiltrating macrophages were similar 
between PBS treated and Treg depleted groups, although – concerning CD80 – the MFI was 
significantly enhanced when compared to blood monocytes of tumor bearing mice (Figure 6.9C). 
B7-H4, an inhibitory member of the B7 family, has been shown to be induced on human 
monocytes after in vitro co-culture with Treg 191. In addition, B7-H4 expression on macrophages 
infiltrating ovarian tumors correlated with the patients’ survival 192. Expression levels of B7-H4 
were determined on tumor-infiltrating macrophages in the RMA-S model. Increased expression 












         
Figure 6.9. Increased MHC class II expression of tumor-infiltrating macrophages in the absence of Treg. (A-
B) C57BL/6 mice were treated with PBS, anti-CD25 mAb, and/or anti-IFN-γ mAb, as indicated, before s.c. 
inoculation with RMA-S cells and 10 days later tumors were removed. (A) Tumor-infiltrating CD11b+F4/80+ cells 
were gated and analyzed for MHC class II expression, as shown in the histograms (one representative analysis out of 
six mice per group is shown). Staining with the specific antibody is indicated by the black line and the corresponding 
isotype control by the grey filled area. (B) Percentages of MHC class II-expressing CD11b+F4/80+ cells (left panel) 
and MFI of MHC class II of CD11b+F4/80+ cells (right panel) in the tumor tissue of PBS (white bars) or anti-CD25 
mAb (black bars) or anti-IFN-γ mAb (grey bars) or anti-CD25 and anti-IFN-γ mAb (checkered bars) treated mice. 
Data show the mean ± SD of three animals per group and are representative of two experiments. *, p< 0.05, using 
Student’s t test. (C-E) C57BL/6 mice were treated with PBS or anti-CD25 mAb, as indicated, before s.c. inoculation 
with RMA-S cells, and 10 days later, tumors (C-E) and blood (C, right panel) were removed. CD11b+F4/80+ cells 
were gated and analyzed for CD86 and CD80 (C), B7-H4 (D) B7-H1, B7-H2, B7-H3 and B7-DC (E) expression. (C-
E) Data show the mean ± SD of three animals per group. 
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of cell surface B7-H4 was detected on tumor-infiltrating macrophages as compared to blood 
monocytes of tumor bearing hosts; however, no differences in B7-H4 expression were observed 
on tumor-infiltrating macrophages between PBS and anti-CD25 treated mice (Figure 6.9D). 
When B7-H4 expression was monitored by intracellular staining, high levels of this molecule 
were detected on both blood and tumor-infiltrating macrophages; however, again, no differences 
were detected between PBS and anti-CD25 treated mice (data not shown). Finally, we analyzed 
the tumor-infiltrating macrophages for the expression of other B7 family members, namely 
B7-H1, B7-H2, B7-H3 and B7-DC. B7-DC, and to a lesser extent B7-H3, expression was 
induced on tumor-infiltrating macrophages as compared to blood monocytes of tumor bearing 
hosts (data not shown). However, no difference was observed between PBS and anti-CD25 
treated mice (Figure 6.9E). B7-H1 and B7-H2 were highly expressed by both blood and tumor-
infiltrating macrophages, but no significant difference could be documented between PBS and 
anti-CD25 treated groups (Figure 6.9E). In conclusion, our data suggest that in the RMA-S tumor 
model expression of B7-H1, B7-H2, B7-H3, B7-H4 and B7-DC on tumor-infiltrating 
macrophages is not controlled by Treg. 
 
6.1.2.2 Enhanced macrophage activity in the absence of Treg 
In order to further characterize the macrophages infiltrating the RMA-S tumors in the presence or 
absence of Treg, cytokine production of freshly isolated tumor-infiltrating macrophages was 
assessed after 12 h of culture in medium alone (Figure 6.10A, upper panel) or in the presence of 
RMA-S cells in combination with LPS to induce maximum release of cytokines (Figure 6.10A, 
lower panel). The results demonstrate consistently higher levels of MIP-1β, MIP-2, MIP-1α, 
IL-6, IL-13 and IL-1β produced by macrophages isolated from tumors of Treg depleted mice 
compared to control mice (Figure 6.10A). Similar amounts of cytokines and chemokines were                         
observed in cultures in the absence or presence of RMA-S cells without the addition of LPS, as 
shown representatively for MIP-2 and IL-6, suggesting that the presence of tumor cells did not 
influence the amounts of cytokines produced upon LPS stimulation (Figure 6.10B). IL-12 (p70), 
IFN-γ and VEGF were not detected. Analysis of the macrophage cytokine profile after 24 h of 
culture revealed a similar pattern (data not shown). In vivo IFN-γ neutralization did not affect the 
production of certain cytokines, such as IL-1β, while it pronouncedly increased the production of 
IL-6 (Figure 6.10C).  
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Figure 6.10. Increased chemokine and cytokine production by tumor-infiltrating macrophages in the absence 
of Treg. (A-B) C57BL/6 mice were treated with PBS (white bars) or anti-CD25 mAb (black bars), before s.c. 
inoculation with RMA-S cells, and 10 days later, tumors were removed. Tumor-infiltrating CD11b+F4/80+ cells were 
purified and cultured in vitro either with medium (A, upper panel) or RMA-S cells in a 5:1 ratio in combination with 
LPS (A, lower panel) or RMA-S cells in a 5:1 ratio alone (B) for 12 h and analyzed for chemokine and cytokine 
production by Bioplex. (C) C57BL/6 mice were treated with anti-CD25 mAb (white bars) or anti-CD25 and anti-
IFN-γ mAb (black bars), before s.c. inoculation with RMA-S cells and 10 days later tumors were removed. Tumor-
infiltrating CD11b+ cells were purified and cultured in vitro either with medium for 24 h and analyzed for cytokine 
production by Bioplex. (A-C) Data are representative of three (A and B) and one (C) experiments. n.d. = not 
detectable. 
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Next, we examined whether macrophages, found in tumors of Treg depleted mice, could 
directly inhibit RMA-S tumor growth. For this purpose, CD11b+ cells were enriched from tumors 
of control or Treg depleted mice; alternatively macrophages (CD11b+ F4/80+) were isolated by 
flow cytometric sorting (purity > 95%). These cells were cultured for 48 h with RMA-S cells and 
proliferation was monitored. Enriched CD11b+ cells (Figure 6.11A, left panel) as well as 
macrophages purified by flow cytometric sorting (Figure 6.11A, right panel) suppressed RMA-S 
tumor cell growth at similar levels at a 10:1 ratio. In addition, they were significantly more potent 
when isolated from tumors of Treg depleted mice compared to cells from the control group 
(Figure 6.11A). Similar results were obtained after 24 h of co-culture, as shown representatively 
for enriched CD11b+ cells (Figure 6.11B). No proliferation was detected when macrophages were 
cultured in the absence of tumor cells. CD11b+F4/80- cells isolated from Treg depleted mice also 
suppressed RMA-S proliferation, in contrast to CD11b+F4/80- cells isolated from PBS treated 
mice (Figure 6.11C). Treg were not present during the tumor cell growth inhibition assay 
indicating that the difference in the suppression between the two groups was not due to Treg 
contaminating the culture of macrophages derived from PBS treated mice (data not shown). 
Interestingly, RMA-S cell growth suppression by CD11b+ cells was completely abrogated when 
IFN-γ was neutralized both in the presence and to a lesser extent – which was not statistically 
significant – in the absence of Treg, pinpointing a role for IFN-γ in enhancing the tumoristatic 
function of macrophages (Figure 6.11D). 
 
6.1.2.3 Macrophages kill RMA-S cells independently of the enzymatic activity of iNOS, 
PGE2 and IDO 
In order to examine the mechanism of suppression of RMA-S proliferation by macrophages, we 
used a trans-well system to separate the macrophages from the RMA-S tumor cells during a 48h 
co-culture. Interestingly, the suppression of RMA-S proliferation was still observed when the 
cells were not in contact (Figure 6.12A), suggesting that a soluble factor was responsible for the 
effect. The suppression of RMA-S proliferation was not due to cell cycle arrest, since the 
presence of macrophages did not have any influence on the CFSE dilution of labeled RMA-S 
cells (Figure 6.12B). Interestingly, dead RMA-S cells, as documented by PI staining, could not be 
detected in the co-culture of macrophages and RMA-S cells, unless the two populations were 
separated with a trans-well insert (Figure 6.12C). At the same time, macrophages became CFSE+  
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Figure 6.11. Enhanced macrophage activity in the absence of Treg. (A-D) C57BL/6 mice were treated with PBS 
or anti-CD25 and/or anti-IFN-γ mAb, as indicated, before s.c. inoculation with RMA-S cells and 10 days later, 
tumors were removed. (A) Enriched CD11b+ cells (left panel) or purified macrophages (CD11b+F4/80+, >95% pure) 
(right panel) were isolated from tumors and co-cultured in vitro with RMA-S cells at the indicated ratios. After 48h 
of co-culture, tumor cell proliferation was monitored by 3H-thymidine incorporation assay. (B) Enriched CD11b+ 
cells were isolated from tumors and co-cultured in vitro with RMA-S cells at the indicated ratios. After 24h of co-
culture, tumor cell proliferation was monitored by 3H-thymidine incorporation assay. (C) Purified CD11b+F4/80+ or 
CD11b+F4/80- cells were isolated from tumors (>95% pure) and co-cultured in vitro with RMA-S cells at a 10:1 
ratio. After 48h of co-culture, tumor cell proliferation was monitored by 3H-thymidine incorporation assay. (D) 
Enriched CD11b+ cells were isolated from tumors and co-cultured in vitro with RMA-S cells at the indicated ratios. 
After 48h of co-culture, tumor cell proliferation was monitored by 3H-thymidine incorporation assay. (A-D) Data 
represent mean ± SD of triplicate cultures and are representative of three (A and B) and one (C and D) experiments. 
*, p<0.05, **, p<0.005, ***, p<0.0001 using Student’s t test. 






















Figure 6.12. Macrophages kill and phagocytose RMA-S cells in vitro. (A-D) C57BL/6 mice were treated with 
PBS or anti-CD25 mAb, as indicated, before s.c. inoculation with RMA-S cells and 10 days later tumors were 
removed. (A) Enriched CD11b+ cells were isolated from tumors and co-cultured in vitro with RMA-S cells in the 
absence or presence of a transwell insert at a 10:1 ratio. After 48h of co-culture, tumor cell proliferation was 
monitored by 3H-thymidine incorporation assay. The data represent mean ± SD of triplicate cultures. (B) RMA-S 
cells (unstained, upper left panel) were labeled with CFSE (t = 0, lower left panel) and cultured in the absence (upper 
right panel) or presence (lower right panel) of CD11b+ cells originating from PBS treated mice. After 48h of co-
culture, CFSE dilution was detected by flow cytometric analysis. The data originate from pooled triplicate cultures. 
(C) Enriched CD11b+ cells were isolated from tumors of PBS treated mice and co-cultured in vitro with RMA-S 
cells, in the absence (left panel) or presence (right panel) of a transwell insert, at the indicated ratios. After 48h of co-
culture, dead RMA-S cells were determined as PI+ cells by flow cytometric analysis. (D) Enriched CD11b+ cells 
were isolated from tumors of PBS treated mice and co-cultured in vitro with CFSE-labeled RMA-S cells at a 40:1 
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when they were in the same chamber with CFSE-labeled RMA-S cells (Figure 6.12D). The same 
results were observed when macrophages were isolated either from PBS or anti-CD25 treated 
mice. In summary, our results suggest that the macrophages induce RMA-S cell death in vitro via 















Figure 6.13. iNOS, PGE2 and IDO are not involved in the suppression of RMA-S tumor growth by 
macrophages. (A) Groups of 8 wt or inducible Nitric Oxide Synthase-/- (iNOS -/-) mice were treated with PBS or 
anti-CD25 mAb, as indicated, before s.c. inoculation with RMA-S cells, and tumor growth was monitored. Each line 
represents one single mouse. (B-C) C57BL/6 mice were treated with PBS or anti-CD25 mAb, as indicated, before 
s.c. inoculation with RMA-S cells, and 10 days later, tumors were removed. Enriched CD11b+ cells were isolated 
from tumors and co-cultured in vitro with RMA-S cells at the indicated ratios in the presence of L-NMMA (B), 
indomethacin (C, left panel), 1MT (C, right panel) or the appropriate controls, as indicated. After 48h of co-culture, 
tumor cell proliferation was monitored by 3H-thymidine incorporation assay. Data represent mean ± SD of triplicate 
cultures. 
 
One effector molecule of activated macrophages is nitric oxide (NO) produced by the 
enzyme inducible nitric oxide synthase (iNOS), which has been shown to have tumor-suppressing 
or tumor-promoting functions 282. In the presence and absence of Treg, tumor growth in iNOS-/- 
mice progressed similarly to the wt controls (Figure 6.13A). In addition, the presence of a NO 
inhibitor, NG-monomethyl-L-arginine (L-NMMA), did not affect macrophage-mediated 
inhibition of tumor cell proliferation in vitro (Figure 6.13B), arguing against a role of NO in the 
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RMA-S model. Prostaglandin E synthase 2 (PGE2) and indoleamine-pyrrole 2,3-dioxygenase 
(IDO) had been initially described as tumor-derived factors involved in immune suppression; 
however, many publications have identified these enzymes in various APC populations, including 
macrophages 283. We addressed the role of these two enzymes by the addition of the specific 
inhibitors indomethacin, to block the activity of PGE2, and 1MT, which blocks IDO activity, 
during the 48h co-culture of RMA-S cells with macrophages. The addition of inhibitors for either 
of these molecules was not able to reverse the suppressive effect of macrophages (Figure 6.13C). 
In summary, macrophages induce RMA-S cell death during their in vitro co-culture via a soluble 
factor, which is independent of the enzymatic activity of iNOS, PGE2 and IDO. 
 
 
6.1.3 Regulatory T cells suppress CD8+ T cell recognition of TAP-deficient tumors 
 
6.1.3.1 CD8+ T cells contribute to RMA-S tumor rejection in the absence of Treg by direct 
recognition of RMA-S cells 
Our depletion experiments implied a role of CD8+ T cells in the memory response against 
RMA-S tumors (Figure 6.4D-F). In addition, CD8+ T cells were the most prominent IFN-γ 
producing cell population in the tumor tissue on day 10 after tumor cell inoculation (Figure 
6.5C). These findings prompted us to further investigate the role of CD8+ T cells in the primary 
anti-tumor response against RMA-S. Interestingly, depletion of the CD8+ T cell compartment 
abrogated RMA-S tumor rejection in the absence of Treg, suggesting that, together with NK cells 
and CD4+ T cells (Figure 6.3C-F), CD8+ T cells also contribute to RMA-S tumor eradication 
during the primary anti-tumor response (Figure 6.14A). In addition, when we analyzed RMA-S 
tumor infiltrates on day 10 after tumor cell inoculation, in the presence or absence of Treg, we 
found increased accumulation of CD8+ T cells in the absence of Treg (Figure 6.14B), as shown 
for other leukocyte populations in our model (Figure 6.7B-C). These data suggest that Treg 
suppress CD8+ T cell accumulation in the tumor, as well as CD8+ T cell mediated anti-tumor 
activity against RMA-S tumor. 
 
 









Figure 6.14. CD8+ T cells contribute to the rejection of RMA-S tumors in the absence of Treg. (A) C57BL/6 
mice were treated with PBS (left panel, n=8) or anti-CD25 mAb (middle panel, n=6), or anti-CD25 and anti-CD8 
mAb (right panel, n=7) before s.c. inoculation with RMA-S cells and tumor growth was monitored. Each line 
represents one single mouse. (B) C57BL/6-Ly5.1+ mice were treated with PBS (white bars) or anti-CD25 mAb 
(black bars) and inoculated s.c. with Ly5.2+ RMA-S cells. Ten days later, tumors were removed and infiltrating 
CD8+ T cells, determined by flow cytometric analysis, were quantified as percentages of total live cells in the tumor. 
*, p<0.05, using Student’s t test. 
 
The recognition of tumor cells by CD8+ T cells in vivo can be either a direct process, by 
the presentation of tumor peptides on the surface of tumor cells in the context of MHC class I 
molecules or an indirect process, by the presentation of tumor antigens on the surface of APC, via 
a mechanism known as cross-presentation 284. In the first case, a mechanism of direct recognition 
of TAP-/- tumors by CD8+ T cells has been recently described 267,285. This recognition is possible 
due to the fact that cells with an impairment in the antigen processing pathway – as is the case for 
RMA-S cells – are not completely negative for MHC class I expression (Figure 6.15, left panel), 
but can present a variety of peptides originating within the endoplasmic reticulum 267. Thus, we 
addressed the question whether CD8+ T cells in our model can directly recognize RMA-S tumor 
cells. For this purpose, we isolated highly purified CD8+ T cells from the LN, DLN and tumor 
tissue of PBS and anti-CD25 treated mice 10 days after RMA-S tumor cell inoculation and co-
cultured them in vitro with fresh RMA-S cells. Supernatants were collected after 18h of culture 
and levels of IFN-γ were determined by ELISA, as a readout for CD8+ T cell activation. Figure 
6.16A, left panel shows that CD8+ T cells isolated from the DLN of Treg depleted mice produced 
IFN-γ in vitro in the presence of RMA-S cells. This was not the case for CD8+ T cells isolated 
from the DLN of PBS treated mice or CD8+ T cells isolated from the non-DLN (LN) either of 
tumor bearing or naïve mice. Most interestingly, CD8+ T cells infiltrating the RMA-S tumors of 
both PBS and anti-CD25 treated mice potently produced IFN-γ in vitro in the presence of RMA-S 
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cells and this production was significantly higher when CD8+ T cells were isolated from the 
tumors of Treg depleted animals (Figure 6.16A, right panel). IFN-γ production by CD8+ T cells 
in this in vitro set-up was absolutely dependent on MHC class I, since co-culture of CD8+ T cells 
with EC7.1 cells, the MHC class I-negative variant of RMA-S (Figure 6.15, right panel), 
abrogated IFN-γ production (Figure 6.16A). Finally, no IFN-γ production was detected when 
CD8+ T cells were cultured alone (Figure 6.16A). In conclusion, our data show that CD8+ T cells 
isolated from RMA-S tumor bearing mice can directly recognize RMA-S cells, via a MHC class I 








Figure 6.15. RMA-S cells express low levels of MHC class I. Representative histogram plots documenting MHC 
class I expression, as assessed by flow cytometry, on RMA-S (left panel) and EC7.1 cells (right panel) . Staining 
with the specific antibody is indicated by the black line and the corresponding isotype control by the grey filled area. 
 
In a second set of experiments, we isolated CD8+ T cells from spleens and LN of mice 
which had rejected RMA-S tumors after Treg depletion and were then rested for at least three 
months to allow the recovery of the Treg compartment. These mice are designated as memory     
mice. In parallel, CD8+ T cells from spleens and LN of naïve mice were also isolated. In both 
cases, CD8+ T cells were co-cultured with RMA-S cells in vitro, and IFN-γ production was 
determined in the supernatants after 18h of co-culture. As shown in Figure 6.16B, CD8+ T cells 
isolated from spleens or LN of naïve mice did not produce any detectable amounts of IFN-γ upon 
co-culture with RMA-S cells. In contrast, CD8+ T cells isolated from spleens or, most 
prominently, from LN of memory mice produced significant amounts of IFN-γ. This production 
was dependent on MHC class I, because when CD8+ T cells were co-cultured with EC7.1 cells, 
IFN-γ production was not observed (Figure 6.16B). These data indicate that CD8+ T cells isolated 
from secondary lymphoid organs of mice, which had rejected RMA-S tumors after Treg 
depletion, can directly recognize RMA-S cells.  
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Figure 6.16. Enhanced direct recognition of RMA-S tumor cells by CD8+ T cells in the absence of Treg. (A) 
C57BL/6 mice were treated with PBS or anti-CD25 mAb, as indicated, and inoculated s.c. with RMA-S cells. Mice 
which were not inoculated with RMA-S cells are designated as naive. Ten days later, draining LN (DLN), non-
draining LN (LN) and tumors were removed. CD8+ T cells were purified from LN and DLN by MACS sorting 
(purity > 80%) or from tumors by FACS sorting (purity > 95%) and cultured alone or in the presence of RMA-S or 
EC7.1 tumor cells for 18h. IFN-γ production was measured in the S/N by ELISA. (B) C57BL/6 mice were treated 
with anti-CD25 mAb before s.c. inoculation with RMA-S cells, rejected RMA-S tumors and rested for at least 3 
months. These mice are designated as memory mice. Mice which were not inoculated with RMA-S cells are 
designated as naïve. CD8+ T cells were isolated from the spleens or LN of naïve or memory mice, and co-cultured 
for 18h alone or in the presence of RMA-S or EC7.1 tumor cells. (A-B) Data represent the mean of duplicates in 
ELISA ± SD and are representative of one (A) and three (B) experiments. *. p < 0,001 in comparison to the PBS 
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6.1.4 Immune intervention in established RMA-S tumors 
 
6.1.4.1 Depletion of Treg in established RMA-S tumors 
We showed that Treg depletion before RMA-S tumor cell inoculation led to tumor rejection 
(Figure 6.3A). Furthermore, we addressed the question whether Treg depletion could enhance 
anti-tumor immunity to mediate the rejection of already established RMA-S tumors. For this 
purpose, we injected mice s.c. with RMA-S cells and allowed the tumors to grow. 10 days after 
tumor cell inoculation, 200µg of anti-CD25 depleting mAb or PBS as a control were injected 
intra- and peritumorally, and tumor growth was observed. Figure 6.17A shows that RMA-S 
tumor growth could be efficiently controlled when the anti-CD25 mAb was administered 2 days 
prior to tumor cell inoculation, while late Treg depletion was not able to influence RMA-S tumor 
growth, when compared to the control group that was treated with PBS. These data suggest that 
depletion of Treg is not by itself sufficient to influence tumor growth of established RMA-S 
tumors. 
 
6.1.4.2 Depletion of NK cells in established RMA-S tumors 
NK cells are absolutely required for RMA-S tumor eradication (Figure 6.3C). Their absence led 
to enhanced tumor growth already in early time points after RMA-S tumor inoculation (Figure 
6.3D, left panel) and this enhanced tumor growth was still present in later time points (Figure 
6.3D, right panel). In later time points of tumor growth, however, it is not obvious whether this 
increased tumor growth is due to the absence of NK cells or to the initial tumor load, which is 
higher when NK cells are not present. In order to investigate the contribution of NK cells in later 
time points of RMA-S tumor growth in the presence or absence of Treg, mice were treated with 
PBS or anti-CD25 mAb before s.c. injection with RMA-S cells; 10 days after tumor cell 
inoculation, anti-NK1.1 depleting mAb or PBS as a control was administered i.p. and tumor 
growth was monitored. Depletion of NK cells 2 days prior to tumor cell inoculation led to 
enhanced tumor growth either in the presence or absence of Treg (Figure 6.17B). Interestingly, 
late depletion of NK cells had only a minor effect on RMA-S tumor growth, in the presence 
(Figure 6.17B, upper panel) or in the absence of Treg (Figure 6.17B, lower panel). These data 
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suggest that NK cells have only a minor contribution to the anti-RMA-S tumor immune response 
in later time points of tumor growth.  
 
 
Figure 6.17. Depletion of Treg or NK cells in established RMA-S tumors does not affect tumor growth. (A) 
Groups of 8 C57BL/6 mice were treated with PBS (left panel) or anti-CD25 mAb administered either on day -2 
(middle panel) or on day +10 (right panel), s.c. inoculated with RMA-S cells and tumor growth was monitored. (B) 
Groups of 7 C57BL/6 mice were treated with PBS or anti-CD25 mAb on day -2 and/or NK1.1 mAb administered 
starting either from day -2 or day +10, as indicated, s.c. inoculated with RMA-S cells and tumor growth was 
monitored. (A-B) Each line represents one single mouse. 
 
 Acquisition of NK cell function during development correlates with high expression of 
the CD11b marker by NK cells 17. In addition, it was reported that various lineages of tumors 
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interfere with NK cell functions, by interrupting their maturation in the bone-marrow 286. To 
address the question whether RMA-S tumor impedes the functional maturation of NK cells, we 
monitored CD11b expression on NK cells in various organs during RMA-S tumor progression. 
Figure 6.18 shows that CD11b expression on NK cells was reduced in the BM, blood, spleen and 
tumor tissue, starting from day 10 after RMA-S tumor cell inoculation, while this reduction 
became more prominent at later time points of tumor growth, as representatively shown for days 
17 and 21 after tumor cell inoculation. Similar results were found when CD43 was used as a 
maturation marker for NK cells (data not shown). These data correlate late NK cell dysfunction 
with reduced CD11b expression in RMA-S tumor bearing mice, without excluding, however, that 




Figure 6.18. Decreased CD11b expression on NK cells during RMA-S tumor progression. C57BL/6 mice were 
injected s.c. with RMA-S cells. After 7, 10, 17 and 21 days, bone marrow, spleens, blood and tumors were removed 
and analyzed for CD11b expression on NK cells by flow cytometry. Data show the mean ± SD of four tumor bearing 
and two naïve animals per time point and are representative of two experiments. *, p<0.05, **, p<0.01 using 
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6.2 Control of anti-tumor immunity by type I IFN 
 
6.2.1 Enhanced RMA-S tumor growth in the absence of type I IFN signaling 
In order to assess the role of type I IFN in the anti-tumor immunity against RMA-S, we s.c. 
injected 1x106 RMA-S tumor cells in wt or IFNAR1-/- mice, which lack the IFNAR1 subunit of 
the IFN-α/β receptor complex 287. Interestingly, we found that mice which could not respond to 
type I IFN exhibited enhanced RMA-S tumor growth, which was statistically significant (Figure 
6.19A). This phenotype could also be observed in wt mice when injected with a neutralizing anti-
IFN-β mAb (Figure 6.19B). These data show that RMA-S tumor growth is under the control of 















Figure 6.19. IFNAR1-/- mice exhibit enhanced RMA-S tumor growth. (A) C57BL/6 wt (left panel, n=5) or 
IFNAR1-/- (right panel, n=7) mice were s.c. inoculated with RMA-S cells and tumor growth was monitored. wt 
versus IFNAR1-/-, p > 0.01, using Koziol test. (B) C57BL/6 wt mice were treated with PBS (left panel, n=5) or anti-
IFN-β mAb (middle panel, n=5) or rat IgG1 mAb (right panel, n=5), inoculated s.c. with RMA-S cells and tumor 
growth was monitored. (A-B) Each line represents one single mouse. The results are representative of two 
independent experiments.  
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6.2.2 Requirement of hematopoietic and non-hematopoietic compartment for 
responsiveness to type I IFN 
We next addressed the question whether the cell targets of type I IFN in our model were derived 
from the hematopoietic or non-hematopoietic compartment of the host. For this purpose, we 
reconstituted lethally irradiated wt and RAG2-/-IFNAR1-/- mice with BM cells isolated from wt or 
IFNAR1-/- mice. Thus, we created the following BM chimeras: wt → wt, in which reconstitution 
leads to type I IFN responsiveness in both the hematopoietic and non-hematopoietic 
compartments, wt → RAG2-/-IFNAR1-/- mice, in which type I IFN responsiveness is reconstituted 
only in the hematopoietic cells, and IFNAR1-/- → wt, in which type I IFN responsiveness is 
present only in the non-hematopoietic compartment. The use of congenic markers (Ly5.1/Ly5.2) 
was employed for the discrimination of host versus donor cells (Table 6.1). Five weeks after BM 
reconstitution, the efficiency of the reconstitution was assessed in the blood of mice by flow 
cytometric analysis and varied between 60 and 90% in individual mice (data not shown). Six 
weeks after BM reconstitution, RMA-S tumor growth was assessed in the chimeric mice, in 
comparison to non-reconstituted IFNAR1-/- mice. Figure 6.20 shows that reconstitution of the 
type I IFN responsiveness in either the hematopoietic or non-hematopoietic compartment of the 
host only partially restored the enhanced RMA-S tumor growth observed in the IFNAR1-/- mice. 
These results show that type I IFN sensitivity within both hematopoietic and non-hematopoietic 
cells is required for RMA-S tumor growth control. 
 
 
Figure 6.20. IFNAR1 signaling on both hematopoietic and non-hematopoietic cells is important in RMA-S 
anti-tumor response. Groups of 9 C57BL/6 wt or RAG2-/-IFNAR1-/- mice were lethally irradiated and reconstituted 
with BM derived either from wt or IFNAR1-/- mice, as indicated. Six weeks after BM reconstitution, chimeric mice, 
as well as IFNAR1-/- mice (n=5) were s.c. injected with RMA-S cells and tumor growth was monitored. Each line 
represents one single mouse. The results are representative of two experiments. 









Table 6.1. Generation of BM chimeras with differential defect in IFNAR1 signaling either on hematopoietic or non-
hematopoietic cells. 
 
6.2.3 Contribution of the hematopoietic compartment for responsiveness to type I 
IFN 
 
6.2.3.1 NK cell cytotoxicity is impaired in IFNAR1-/- mice 
NK cells are absolutely required for the control of RMA-S tumor growth (Figure 6.3C-D). 
Therefore, we addressed the question whether NK cell function is impaired in IFNAR1-/- mice. 
For this purpose, NK cells were isolated from the spleens of wt or IFNAR1-/- mice by magnetic 
separation and their cytotoxic ability was tested against the NK cell sensitive tumor cell line 
YAC-1 or against RMA-S cells in a standard in vitro 6h 51Cr release assay. Interestingly, NK 
cells isolated from the spleens of IFNAR1-/- mice had significantly reduced ability to kill YAC-1 
or RMA-S targets when compared to NK cells from wt mice (Figure 6.21A). Thus, NK cell 
cytotoxicity is impaired in IFNAR1-/- mice. 
 
6.2.3.2 Macrophage tumoristatic activity is not impaired in IFNAR1-/- mice 
Another important effector cell population identified in the RMA-S tumor model is macrophages, 
which can suppress RMA-S proliferation in vitro (Figure 6.11). Macrophage tumoristatic activity 
against RMA-S tumor cells was assessed in the IFNAR1-/- mice. Tumor infiltrating CD11b+ cells 
isolated from RMA-S tumors grown in wt or IFNAR1-/- mice were enriched with magnetic cell 
sorting 10 days after tumor cell inoculation and co-cultured in vitro with RMA-S tumor cells. 
RMA-S tumor cell proliferation was assessed after 48h using 3H-thymidine incorporation assay. 
As shown in Figure 6.21B, CD11b+ cells from IFNAR1-/- mice were equally efficient to suppress 
Hematopoietic cellsLy5.1+ wtLy5.2+ IFNAR1-/-3
BothLy5.2+ IFNAR1-/-—4
Non-hematopoietic cellsLy5.2+RAG2-/- IFNAR1-/-Ly5.1+ wt2
—Ly5.2+ wtLy5.1+ wt1
IFNAR1 DEFICIENCYHOSTBM DONORGROUP
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RMA-S tumor cell growth in vitro as CD11b+ cells isolated from wt mice. These finding suggests 
















Figure 6.21. Impaired NK cell but normal macrophage function in the IFNAR1-/- mice. (A) NK cells were 
isolated from spleens of wt (white points) or IFNAR1-/- (black points) mice and co-cultured in vitro with 51Cr-
labelled YAC-1 (left panel) or RMA-S (right panel) target cells at the indicated ratios. After 6h of co-culture, 51Cr 
release was measured in the S/N. Data represent mean ± SD of triplicate cultures. *, p<0.05, **, p<0.001, ***, 
p<0.0001 using Student’s t test. (B) C57BL/6 wt (white bars) or IFNAR1-/- (black bars) mice were s.c. inoculated 
with RMA-S cells and 10 days later tumors were removed. CD11b+ cells were isolated from the tumors and co-
cultured in vitro with RMA-S cells at the indicated ratios. After 48h of co-culture, tumor cell proliferation was 
monitored by 3H-thymidine incorporation assay. Data represent mean ± SD of triplicate cultures. (C) C57BL/6 wt 
(white bars) or IFNAR1-/- (black bars) mice were s.c. inoculated with RMA-S cells and 10 days later tumors were 
removed and infiltrating CD11b+, Gr-1+, CD4+, CD8+ and NK (NK1.1+CD3-) cells were determined by flow 
cytometric analysis and quantified as percentages of total live cells in the tumor. Data show the mean ± SD of 3 
animals per group. 
 
6.2.3.3 Intratumoral leukocyte accumulation is not impaired in IFNAR1-/- mice 
Increased numbers of myeloid cells 287 and reduced numbers of NK cells 259 have been reported 
in the blood of IFNAR1-/- mice. We addressed the question whether leukocyte accumulation in 
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the RMA-S tumors is impaired in IFNAR1-/- mice. For this purpose, we determined the quantity 
of various tumor infiltrating leukocyte subpopulations as percentages of total live cells in the 
tumor in wt and IFNAR1-/- mice on day 10 after RMA-S tumor cell inoculation. The mean tumor 
size of the two groups was comparable at this time point. Flow cytometric analysis revealed that 
CD11b+ cells, Gr-1+ cells, CD4+ T cells, CD8+ T cells and NK cells were infiltrating the tumors 
of wt and IFNAR1-/- mice in similar amounts (Figure 6.21C). These data indicate that, although 
the numbers of some cell populations are misbalanced in the blood of IFNAR1-/- mice, the 
leukocyte accumulation in the RMA-S tumors is not impaired and is comparable to the wt 
situation. 
 
6.2.4 Contribution of the non-hematopoietic compartment for responsiveness to 
type I IFN 
 
6.2.4.1 Angiogenesis is impaired in IFNAR1-/- mice 
Figure 6.20 shows that type I IFN responsiveness is required in the non-hematopoietic 
compartment. To address the importance of this finding, angiogenesis pattern and vessel 
functionality were observed in RMA-S tumors of wt and IFNAR1-/- mice. For this purpose, wt or 
IFNAR1-/- mice were injected with FITC-labeled Lycopersicon esculentum lectin on day 10 of 
tumor growth and the tumor vasculature was observed by confocal microscopy. Long vessels 
with normal branching were commonly present within the tumors of wt mice, and no 
extravasated FITC-lectin could be detected (Figure 6.22A, left panel). On the other hand, 
structural irregularity, heterogeneity and leakiness were common features of the vessels in the 







Table 6.2. Generation of BM chimeras with differential defect in IFNAR1 signaling either on hematopoietic or non-
hematopoietic cells. 
Hematopoietic cellsLy5.1+ wtLy5.2+ IFNAR1-/-3
BothLy5.2+ IFNAR1-/-Ly5.2+ IFNAR1-/-4
Non-hematopoietic cellsLy5.2+ IFNAR1-/-Ly5.1+ wt2
—Ly5.2+ wt—1
IFNAR1 DEFICIENCYHOSTBM DONORGROUP
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In a further step, we wanted to address the question whether the observed defect in 
angiogenesis depends solely on IFNAR1 signaling on non-hematopoietic cells or factors 
produced by infiltrating leukocytes are also involved. For this purpose, we created BM chimeras, 
where either the hematopoietic or non-hematopoietic system was impaired in IFNAR1 signaling 
(Table 2). As expected, normal vessel pattern was observed in the wt tumors, while disoriented 
vessel formation and destroyed vessels, as documented by the presence of extravasated FITC-
lectin, were observed in the tumors of IFNAR1-/- mice (Figure 6.22B). Interestingly, most vessels 
infiltrating the tumors of either wt → IFNAR1-/- or IFNAR1-/- → wt chimeric mice exhibited an 
abnormal branching pattern, quite similar to the one observed in the tumors of IFNAR1-/- mice 
(Figure 6.22B). In summary, these data support that angiogenesis is impaired in the RMA-S 
tumors of IFNAR1-/- mice and both hematopoietic and non-hematopoietic cells are responsible 

















Figure 6.22. Impaired angiogenesis in the IFNAR1-/- mice. Groups of 3 C57BL/6 wt or IFNAR1-/- mice (A) or 
groups of 3 C57BL/6 wt mice or wt > IFNAR1-/- or IFNAR1-/- > wt or IFNAR1-/- > IFNAR1-/- BM chimeras (B) 
were s.c. inoculated with RMA-S cells. (A-B) Ten days later, FITC-labeled Lycopersicon esculentum lectin was 
injected into the mice and tumor vasculature was observed in unfixed tumors by confocal microscopy. 
 
wt IFNAR1-/-








7.1 Suppression of innate immune cells by Treg 
 
In the first part of this study, we investigated the role of Treg on the innate immune response 
against the lymphoma RMA-S. Our study revealed that Treg suppress RMA-S tumor rejection by 
inhibiting the IFN-γ-mediated accumulation of leukocytes, including macrophages at the tumor 
site. Most importantly, we demonstrated that highly activated, tumoristatic macrophages 
accumulated in the tumor tissue in the absence of Treg, unraveling a novel aspect of Treg-
mediated suppression of anti-tumor immune responses in vivo. 
During the last years, the role of Treg as professional suppressive cells has been 
confirmed by several studies 288. Treg were shown to exert an immunosuppressive role in 
multiple disease settings, including anti-tumor responses. Indeed, Treg were shown to accumulate 
in high numbers in both murine and human tumors, as well as in secondary lymphoid organs 
180,181,289. This increased accumulation can be due either to proliferation of preexisting Treg 290 or 
to the conversion of CD4+CD25- T cells into Treg, which has been described to take place in the 
periphery under certain conditions 291. In the s.c. RMA-S mouse lymphoma model, we detected 
high percentages of CD4+Foxp3+ Treg among CD4+ T cells in secondary lymphoid organs, as 
well as infiltrating the tumor tissue. Foxp3 expression coincided with CD25 expression on CD4+ 
T cells, which in turn correlated with suppressive activity in an in vitro assay. Most importantly, 
in vivo depletion of CD25+ cells led to RMA-S tumor rejection, pinpointing the suppressive role 
of the CD4+CD25+Foxp3+ Treg in the control of the MHC class I-deficient RMA-S tumor. 
There have been many reports addressing the suppressive effect of Treg on T cells in the 
context of autoimmune diseases, infectious models and tumor immunity. It has been suggested 
that human Treg have overlapping TCR specificities as Tcon and would be able to suppress in an 
antigen-specific manner 292. Thus, the concept that Treg would suppress innate immune cell 
functions, which are not antigen specific, is intriguing. Nevertheless, there have been some 
reports which documented the suppressive effect of Treg on cells of the innate immune system 
185-194. Previous studies showed that Treg inhibited NK cell effector functions in both mouse and 
human systems 185,186,293-295. In the absence of Treg, 3LL Lewis Lung carcinoma cells, RAE-1-
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transfected B16 melanoma, and RAE-1-transfected RMA-S lymphoma cells, all of which express 
high levels of the NKG2D ligand RAE-1, were more efficiently controlled in vivo 185,186. These 
data suggest that Treg can directly inhibit NK cell activation towards NKG2D ligand-expressing 
tumor cells in vivo. Our depletion experiments indicated that NK1.1+ cells are necessary but not 
sufficient for tumor rejection in the absence of Treg. Notably, in our experiments, the early 
growth of RMA-S tumors, which do not express NKG2D-ligands, was retarded by NK cells, 
irrespective of whether Treg were present or absent. Our data indicate that the early NK cell-
mediated tumor control, most likely due to direct tumor cell killing, was not hampered by Treg. 
This suggests that distinct NK cell activation pathways might be differentially controlled by Treg. 
We discovered that IFN-γ, produced by NK cells, CD8+ T cells and to a lesser extent by 
CD4+ T cells, was absolutely required for the eradication of RMA-S cells in Treg depleted mice. 
In addition, our data revealed that high amounts of IFN-γ were detected in the tumor and that 
these levels were significantly elevated in the absence of Treg. IFN-γ can exert anti-tumor 
immunity by various mechanisms. First, IFN-γ can directly suppress tumor growth. Nevertheless, 
IFN-γ did not influence RMA-S cell proliferation in vitro (data not shown).  IFN-γ has also been 
shown to inhibit angiogenesis in some tumors 278,296. In our tumor model, CD31 or MECA-1 
staining of tumor sections obtained at day 10 did not show any significant difference in vessel 
number or localization in the presence or absence of Treg (data not shown). In addition, vessel 
integrity remained unchanged in the absence or presence of Treg, suggesting that angiogenesis 
was not altered in Treg depleted mice. 
IFN-γ has been shown to facilitate leukocyte migration into tumors, directly or indirectly, 
by the modulation of certain chemokines and chemokine receptors 297. In order to gain insight 
into the immune response within the tumor, we analyzed tumor-infiltrating cells at day 10, before 
RMA-S tumors were rejected in Treg depleted mice. At this time point, the tumor size between 
control and Treg depleted mice was similar. We detected that mostly CD11b+ cells −consisting of 
macrophages, dendritic cells and granulocytes− and comparably lower amounts of NK cells, 
CD4+ and CD8+ T cells accumulated in the tumor tissue. Importantly, all these cell populations 
were significantly increased in mice depleted of Treg. In this context, it has also been shown that 
Treg inhibited tissue infiltration of conventional CD4+ T cells in a diabetes model 298. In addition, 
injection of Treg into nude mice inhibited accumulation of NK cells to RMA-S cells injected into 
the peritoneum 186. In these studies, the Treg mediated mechanisms responsible for the inhibition 
of cell accumulation were not defined. In a recent study, it was reported that Treg could induce 
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NK and CD8+ T cell death in a granzyme B- and perforin-dependent fashion 187, suggesting that 
this may be the mechanism via which Treg control NK cell numbers also in our tumor model. In 
a study involving large cohorts of human colorectal cancers, a high density of immune cells, 
including T cells, correlated with longer survival in patients, suggesting that in situ analysis of 
tumor infiltrating immune cells may be a valuable prognostic tool in the treatment of some types 
of malignancies 279. In the RMA-S s.c. tumor model, higher density of infiltrating cells also 
correlated positively with tumor regression in the absence of Treg. Our experiments further show 
that the increased CD11b+ and CD4+ T and CD8+ T cell accumulation in the tumors of Treg 
depleted mice was dependent on IFN-γ. Furthermore, the presence of IFN-γ was absolutely 
required for NK cell accumulation in the tumor tissue. 
Finally, IFN-γ is involved in macrophage activation 299. Indeed, in the absence of Treg, 
we did not only find high numbers of macrophages in the tumor tissue but these cells also 
displayed increased MHC class II expression. The upregulation of MHC class II was dependent 
on IFN-γ. These data suggest that increased IFN-γ levels in the absence of Treg lead to enhanced 
macrophage activation. We assume that these macrophages, due to enhanced levels of MHC class 
II, have the potential to induce efficient activation of CD4+ T cells at the tumor site. In addition, 
increased numbers of MHC class II high DC accumulated in the tumor in the absence of Treg. 
Taken together, this increase of antigen-presenting cells with high MHC class II expression may 
be instrumental for efficient presentation of tumor antigens to CD4+ T cells in the absence of 
Treg. Indeed, CD4+ T cells are absolutely required for tumor rejection in these mice. Moreover, 
the absence of Treg led to the generation of immunological memory. 
Tumor-associated macrophages represent the major infiltrating component of many 
tumors and can have multi-faceted functions depending on the tumor microenvironment 103. In 
several experimental tumor models, activation of an inflammatory response mediated by 
macrophages promoted tumor progression 300. In addition, a subpopulation of myeloid cells, 
designated as MDSC (myeloid-derived suppressor cells), expressing the markers Gr-1 and 
CD11b, was shown to suppress T cell responses 301. We have evidence that the tumor-infiltrating 
macrophages in our model did not suppress, but rather activated T cell proliferation (data not 
shown). Therefore, our data suggest that in our model, tumor-infiltrating macrophages are distinct 
from myeloid-derived suppressor cells. Studies have shown that macrophages produce 
inflammatory chemokines and cytokines, which recruit and activate other cell types 103. In 
addition, tumor-infiltrating macrophages have the potential to directly control tumor cell 
Ioanna E. Galani                                                                           Discussion 
 90
proliferation when appropriately stimulated, e.g. by potently activated T cells in the presence of 
IFN-γ or after CpG treatment 109,110. Our experiments showed that, in the absence of Treg, 
macrophages isolated from tumors produced higher amounts of chemokines and inflammatory 
cytokines, which could lead to efficient cell recruitment and activation. Most importantly, 
enriched CD11b+ cells and macrophages isolated from tumors in the absence of Treg inhibited 
tumor cell growth more potently, as compared to cells isolated from control tumors. The 
suppressive effect of macrophages on the growth of RMA-S cells in vitro was abrogated when 
IFN-γ was neutralized in vivo during the anti-tumor immune response. One effector molecule 
expressed by activated macrophages is nitric oxide (NO) produced by the enzyme inducible nitric 
oxide synthase (iNOS), which has tumor-suppressing or tumor-promoting functions. In the 
presence and absence of Treg, tumor growth in iNOS-/- mice progressed similarly to the wt 
controls. In addition, the presence of a NO inhibitor did not affect macrophage-mediated 
inhibition of tumor cell proliferation in vitro. Similarly, the addition of inhibitors against the 
activity of PGE-2 and IDO did not affect RMA-S tumor growth in the presence of macrophages 
in vitro. These data argue against a role of the enzymes NO, PGE-2 and IDO in our model. 
Of note, IFN-γ neutralization had a diverse effect on the pro-inflammatory cytokine 
profile in the absence of Treg; while it did not affect IL-1β production by CD11b+ cells, it 
strongly enhanced IL-6 production. This is of importance, since IL-6 in combination with TGF-β 
has been shown to be necessary for the differentiation of naïve T cells into Th17 cells 302. It is 
also reported that IFN-γ can negatively regulate Th17 cell differentiation and vice versa 303. It is 
possible that the presence of IFN-γ in the absence of Treg suppresses Th17 polarization and 
protects the host from autoimmune reactions, which have often been linked to Th17 cells 304. Of 
note, IL-17 was detected in low amounts in tumor lysates from both control and Treg depleted 
animals 10 days after RMA-S tumor inoculation (data not shown). It will be of interest to 
quantify Th17 levels in the RMA-S tumor tissue after IFN-γ neutralization. 
It has been reported that Treg suppress macrophage activation and effector function 
directly in vitro 190,193. In vivo, Kim et al. documented that macrophage expansion was under the 
control of Treg under steady state conditions in adult mice 195. Kryczek et al. showed 
upregulation of the B7 family member B7-H4 (B7S1, B7-S1, B7x) on isolated human monocytes 
by Treg after direct contact in an in vitro co-culture 191. In mice, B7-H4 is expressed upon 
activation on B cells, T cells and monocytes and was shown to negatively regulate T cell 
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responses 305. Its ligand remains to be identified, but evidence support that it is expressed on 
activated T cells. In addition, B7-H4 expression on macrophages infiltrating ovarian tumors 
correlated with the patients’ survival 192. In our tumor model, no difference in the expression of 
B7-H4 was observed on tumor-infiltrating macrophages between control and Treg depleted mice. 
Our study reveals a novel role of Treg mediated suppression of macrophage function in a tumor 
model in vivo. Whether the suppression of macrophages requires a direct Treg/macrophage 
interaction, as observed for Treg/DC interaction in vivo 197, or is rather due to indirect effects via 
inhibition of other immune cells, requires further investigation. Kryczek et al showed that Treg 
directly suppressed macrophages in an in vitro co-culture 191. Our experiments demonstrate that 
in vivo macrophage accumulation at the tumor site was absolutely dependent on CD4+ T cells and 
to a lesser extent on NK cells. In addition, increased macrophage accumulation in the absence of 
Treg, MHC class II upregulation and tumoristatic activity of macrophages were all dependent on 
IFN-γ, which in turn Treg suppressed its production. We assume that, in our model, Treg 
suppressed IFN-γ production by lymphocytes, which in a second step interfered with macrophage 
activation and accumulation at the tumor site. 
The mechanism that Treg use to exert their suppressive function in the RMA-S model is 
still under investigation. Neutralization of TGF-β or blocking IL-10R by specific mAbs, two 
pathways that have been linked to Treg-mediated suppression 281, did not influence tumor growth 
and did not lead to tumor rejection in our model, suggesting that neither TGF-β nor IL-10 are 
required for Treg mediated suppression in vivo. Recently, it was reported that IL-35 is 
specifically produced by Treg and not effector T cells and can mediate suppression 306. So far, 
reagents to block this cytokine in vivo are not available. 
Unexpectedly, we discovered an important contribution of CD8+ T cells in the rejection of 
the MHC class I-deficient RMA-S tumor in the absence of Treg, as well as during the memory 
response against a secondary challenge to RMA-S cells. In this context, Kelly at al. reported that 
CD8+ T cells mediated memory responses after rejection of RMA-S cells transfected with CD70 
or CD80. The mechanism, however, via which CD8+ T cells would recognize RMA-S cells was 
not addressed in this studies 20,307. In our model, CD8+ T cells isolated from RMA-S tumor tissue 
during the primary anti-tumor response or from the secondary lymphoid organs of mice which 
had previously rejected RMA-S tumors after Treg depletion were able to directly recognize 
RMA-S cells in an in vitro co-culture. It has been reported that the TAP-negative RMA-S cells, 
which express only very low amounts of MHC class I on their surface, present a range of 
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antigens – referred to as TEIPP – which are TAP-independent and can be recognized by CD8+ T 
cells 267,285. It is possible that Treg depletion increases the potential recognition of such peptides 
by CD8+ T cells, allowing potent antigen-specific responses to take place even against targets 
which express very low amounts of MHC class I. This observation might offer new therapeutic 
approaches against human cancers, which often have low MHC class I expression. 
The manipulation of Treg is currently evaluated in clinical trials in tumor patients 209,210. It 
will be informative to monitor numbers and activation status of tumor-infiltrating macrophages in 
patients undergoing Treg depletion or treated with other immunotherapeutic protocols and to 
correlate these data with the clinical outcome. The results of our study may have substantial 
impact on the design of novel strategies in anti-cancer therapy to strengthen both the innate and 
adaptive immune responses against cancer. 
 
 
7.2 The role of endogenous type I IFN in the anti-tumor response 
 
In the second part of this study, we addressed the role of endogenously produced type I IFN in 
the anti-tumor response against the MHC class I-deficient lymphoma RMA-S. We showed that 
RMA-S tumor growth is accelerated in mice, which are non-responsive to type I IFN. Our data 
demonstrate that this acceleration in tumor growth correlates with defects in NK cell activity and 
vessel network formation at the tumor site. 
Type I IFN have been extensively used in the treatment of various types of cancer, 
although their mechanism of action is not completely clear 252. In vitro high doses of type I IFN 
promote cell cycle arrest in various cell types 248,249. It is believed that this may be their 
mechanism of action after exogenous administration in cancer patients. The study of RMA-S 
tumor growth in the IFNAR1-/- mice allows dissecting the effect of type I IFN on the host and on 
the tumor cells. The accelerated tumor growth observed in these mice after s.c. RMA-S 
inoculation showed that type I IFN need to signal to the host’s cells for an efficient anti-tumor 
response. Our findings are in concordance with other reports, which demonstrated a role for type 
I IFN in tumor immunosurveillance using IFNAR1-/- 129/Sv mice 258. In this study, transplanted 
tumors originating from MCA-induced fibrosarcomas were under the control of type I IFN-
responsive hematopoietic cells. In the RMA-S model, by the generation of BM chimeras, we 
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showed that cells of both the hematopoietic and non-hematopoietic system responded to type I 
IFN and were required for an efficient anti-tumor response. The different tumor origin in these 
models may account for this difference in the immune response. In addition, it was reported that 
IFN-α did not affect the proliferation of RMA-S cells in vitro 259. Our results pinpoint a role for 
endogenously produced type I IFN in the anti-tumor response against the RMA-S tumor, and in 
addition suggest a mechanism of action, which is dependent on the host’s response to type I IFN. 
Type I IFN can exert multi-faceted functions in the hematopoietic system. Type I IFN can 
promote CD8+ T cell-mediated responses, induce the maturation of DC and indirectly enhance 
NK cell cytotoxicity 87,231,232. We addressed the question which cell population was impaired 
during the anti-tumor response in the IFNAR1-/- mice. MHC class I-deficient RMA-S tumor 
growth is under the control of NK cells. Indeed, we found that NK cells derived from IFNAR1-/- 
mice exhibited impaired cytotoxicity against two different tumor targets in vitro. This finding is 
in corcondance with a report from another group, which in addition observed reduced NK cell 
numbers in the spleens of IFNAR1-/- mice 259. This observation pinpoints to a role for type I IFN 
in the homeostasis of NK cells, and not only in their function during an immune response. It is 
known that IFN-β, binding to the IFNAR1, is constitutively produced by fibroblasts and 
macrophages 287, so it is possible that these constant levels of IFN-β contribute to NK cell 
homeostasis. Interestingly, despite the reduced occurrence of NK cells in the spleens of 
IFNAR1-/- mice, we observed that the accumulation of NK cells – as well as other leukocyte 
populations – at the tumor site was not impaired. This observation suggests that the factors 
responsible for the recruitment of leukocytes at the tumor tissue during the anti-tumor response to 
RMA-S cells are not under the control of endogenous type I IFN. We showed that, in addition to 
NK cells, in the RMA-S model macrophages are important effector cells, which mediate a 
tumoristatic effect. It was reported that the response of macrophages to CSF-1 and LPS was 
impaired in IFNAR1-/- mice 287. In a co-culture of macrophages and RMA-S cells, the suppressive 
effect of macrophages on RMA-S tumor growth was indistinguishable between macrophages 
originating from wt and IFNAR1-/- mice, suggesting that the anti-tumor response of macrophages 
might not be tightly regulated by type I IFN. Our study correlated the acceleration in tumor 
growth in IFNAR1-/- mice with an impaired function of NK cells, without excluding, 
nevertheless, that other cell populations might be affected. 
An effect of type I IFN on non-hematopoietic cells has been documented. Treatment with 
type I IFN caused damage on endothelial cells, which led to tumor necrosis 250. Anti-angiogenesis 
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factors which inhibit blood vessel growth are commonly used in cancer immunotherapy based on 
the notion that angiogenesis is absolutely required for tumor growth 308. IFN-α has been 
introduced into clinical applications as an anti-angiogenic factor to treat haemangiomas 309,310. In 
IFNAR1-/- mice, we observed increased vascularization, albeit deregulated. The use of in vivo 
fluorescent angiography revealed a difference in vascular architecture of the tumors of IFNAR1-/- 
versus wt mice, and namely a less organized blood vessel network in the IFNAR1-/- mice. In 
addition, extravasated FITC-lectin was detected. The latter finding pinpoints to the lack of 
sufficient pericyte recruitment, which form a layer around the endothelial cells. Stainings of 
tumor sections for pericyte markers should address these questions. It is suggested that 
angiogenic factors, such as basic fibroblast growth factor (bFGF), downregulate adhesion 
molecules on endothelial cells, which are involved in leukocyte-vessel wall interactions, such as 
intercellular adhesion molecule (ICAM)-1 311.This correlated with decreased leukocyte 
infiltration of the tumors and thus to reduced immune surveillance. We found that leukocyte 
accumulation in the tumors of IFNAR1-/- mice, as assessed by flow cytometry, was similar to the 
wt levels, suggesting that this mechanism might not be impaired in IFNAR1-/- mice. 
Nevertheless, it is possible that leukocyte localization within the tumor tissue is different between 
wt and IFNAR1-/- mice. Analysis of tumor tissue sections can address the question whether 
leukocytes are uniformely distributed throughout the tumor mass in wt and IFNAR1-/- mice. In 
summary, our findings show that endogenous type I IFN are important for the architecture of 
tumor vasculature and the formation of mature blood vessels; the contribution of an organized 
vessel network to tumor growth control needs to be elucidated. 
The phenotype of impaired anti-tumor response in the IFNAR1-/- mice could be mimicked 
by the administration of an anti-IFN-β neutralizing mAb in vivo. This result implicates IFN-β 
production during the anti-tumor response, without excluding a role also for the different 
subtypes of IFN-α. During an anti-viral response, IFN-β and/or IFN-α4 genes are readily induced 
and subsequently induce the production of the other subtypes of IFN-α 224,230. A similar 
mechanism may as well take place during the anti-tumor response. We were able to detect both 
IFN-β and IFN-α mRNA in leukocytes infiltrating the RMA-S tumors 10 days after tumor 
inoculation (data not shown), showing that at least some subtype of IFN-α is produced during the 
anti-tumor response. Due to the lack of efficiently neutralizing anti-IFN-α mAb, we were not 
able to address the importance of IFN-α in vivo. The use of an anti-IFN-β neutralizing mAb also 
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excluded a possible developmental defect in the IFNAR1-/- mice which could be responsible for 
the observed phenotype. The identification of the type I IFN-producing cell population during the 
anti-tumor response remains still unclear. In principle, all cells are capable  of producing type I 
IFN during a viral infection, although pDC are specialized IFN-producing cells producing high 
amounts of type I IFN after TLR stimulation 229. We could detect IFN-β and IFN-α mRNA on 
leukocytes of both myeloid and non-myeloid lineage based on CD11b marker discrimination, and 
in addition IFN-β mRNA on non-hematopoietic cells (data not shown), suggesting that – similar 
to an anti-viral response – the production of type I IFN during the anti-tumor response can have 
multiple sources. Nevertheless, the stimuli which can induce the production of type I IFN during 
the tumor growth remain unknown. 
Further investigations on the source and function of endogenous type I IFN during the 
anti-tumor response will help to identify new therapeutic targets for cancer immunotherapy, and 
assist the efficacy of the presently applied clinical treatments which are based on the use of type I 
IFN.
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9 ABBREVIATIONS 
(listed in alphabetical order) 
 
1MT 1-Methyl- L -Tryptophan 
α- anti- 
ACK Ammonium Chloride potassium phosphate buffer 
ADCC Antibody-Dependent Cell-mediated Cytotoxicity 
APC AlloPhycoCyanin 
APC Antigen Presenting Cells 
BCR B Cell Receptor 
bFGF basic Fibroblast Growth Factor 
BM Bone Marrow 
CD Cluster of Differentiation 
CSF Colony Stimulating Factor 
CFSE CarboxyFluorescein Succinimidyl Ester 
cpm counts per minute 
CTLA-4 Cytotoxic T-lymphocyte-associated Antigen-4 
Cy5 Cyanine 5 
DC Dendritic Cells 
ddH2O double distilled water 
DLN Draining LN 
DMSO DiMethylSulfOxide 
ELISA Enzyme-Linked ImmunoSorbent Assay 
EMCV EncephaloMyoCarditis Virus 
E:T Effector to Target 
FACS Fluorescence-Activated Cell Sorting 
FITC Fluorescein-IsoThioCyanate 
FSC Forward SCatter 
g gram 
GM-CSF Granulocyte/Macrophage CSF 
GITR Glucocorticoid-Iinduced TNF-receptor family-Related 
h hour 
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HLA Human Leukocyte Antigen 
HSV Herpes Simplex Virus 
IBD Inflammatory Bowel Disease 
ICAM InterCellular Adhesion Molecule 
IDO Indoleamine-pyrrole 2,3-dioxygenase 
IFN Interferon 
IFNAR1 Interferon-α Receptor 1 
Ig Immunoglobulin 
IL InterLeukin 
iMC immature Myeloid Cells 
iNOS inducible Nitric Oxide Synthase 
i.p. intraperitoneal 
i.v. intravenous 
IPEX Immune dysregulation, Polyendocrinopathy, Enteropathy, 
X-linked 
L/D-NMMA L/D-NG-MonoMethyl Arginine 
LN Lymph Node 
LPS LipoPolySaccharide 
mAb monoclonal Antibody 
MACS Magnetic Cell Sorting 
µC microCurie 
MCA MethylCholAnthrene 
MCMV Murine CytoMegaloVirus 
MDA5 Melanoma Differentiation-Associated protein 5 
MDSC Myeloid-Derived Suppressor Cells 
MHC Major Histocompatibility Complex 
Mφ Macrophage 
MFI Mean Fluorescence Intensity 
µg microgram 
min minute 
MIP Macrophage Inflammatory Protein 
µl microlitre 
ml mililitre 




MME Macrophage MetalloElastase 
MMP Matrix MetalloProteinase 
MSC Myeloid Suppressor Cells 
NK Natural Killer 
NKG2D NK Group 2 member D 
nm nanometer 
NO Nitric Oxide 
NOD Nucleotide-Oligomerization Domains 
OD Optical Density 
O/N Over Night 
PAMP Pathogen-Associated Molecular Patterns 
PBL Peripheral Blood Lymphocytes 
PBS Phosphate Buffered Saline 
pDC plasmacytoid DC 




pH potential Hydrogeni 
PI Propidium Iodide 
PGE2 Prostaglandin E synthase 2 
Poly(I:C) PolyInosinic-PolyCytidylic acid 
Prf Perforin 
PRR Pattern-Recognition Receptors 
RAE-1 Retinoic Acid Early inducible-1 
RAG Recombination-Activation Gene 
rpm rounds per minute 
RT Room Temperature 
s.c. subcutaneous 
SD Standard Deviation 
S/N SuperNatant 
SSC Side SCatter 
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TAA Tumor-Associated Antigens 
TAM Tumor Associated Macrophages 
Tcon conventional T cells 
TCR T Cell Receptor 
TGF-β Transforming Growth Factor-β 
TID Type I Diabetes 
TLR Toll-Like Receptors 
TNF Tumor Necrosis Factor 
TRAIL TNF–Related Apoptosis-Inducing Öigand 
Treg Regulatory T cells 
TSA Tumor-Specific Antigens 
VEGF Vascular Endothelial Growth Factor 
wt wild type 
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